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Chapter I 
INTRODUCTION 
MOLECULAR ALTERATIONS ASSOCIATED WITH 
PROSTATE CANCER DEVELOPMENT 
Yahya Tamimi, Marion J. G. Bussemakers and Jack A. Schalken. 
Department of Urology/Urological Research Laboratory, University Hospital Nijmegen, 
Nijmegen, The Netherlands. 
Based on: Progress and Controversies in Oncological Urology IV (PACIOU IV): Recent 
Advances in Prostate Cancer and BPH, 11-13 April 1996, Rotterdam, The Netherlands, 
Parthenon Publishing, UK, F.H. Schroeder, Ed. 
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1. CLINICAL BACKGROUND 
Prostate cancer, the malignancy with the highest incidence rate in the western male 
population, is characterized by the fact that at clinical presentation, the majority of 
patients have disease extended beyond the prostate, i.e., capsular penetration and/or 
established locoregional or distant metastases. For prostate cancer the clinical 
consequences of established metastatic disease are profound, since no curative therapy is 
available. Systemic palliative methods, based on androgen ablation, are usually 
successful, but of limited duration. The outgrowth of androgen-insensitive cells is 
inevitable and will eventually result in the patient's death. 
Patients with localized tumors can be cured by radical prostatectomy. A considerable 
proportion of these patients, however, will show clinical progression to metastatic disease. 
Obviously, identification of these patients at risk is of great importance. Moreover, it is 
likely that the number of patients with small localized tumors will steadily increase as a 
consequence of incidental and/or systematic screening of the male population older than 
50 years. In this group three categories are present which, as yet, cannot be 
discriminated: (1) the patients with small tumors that do not need any treatment; (2) those 
who should undergo a radical prostatectomy but have a low risk for clinical progression; 
and (3) the high-risk patients with tumors which are likely to progress to metastatic 
disease. 
At this moment, no accepted method is available to make this distinction, which makes 
systematic screening programs at least questionable. Therefore, methods for prediction of 
the metastatic potential of tumor cells are urgently needed. Many research laboratories are 
using molecular approaches to this problem. These approaches are all based on the 
question whether molecular differences at the DNA, RNA or protein level can be 
identified that can serve as progression markers for malignant prostatic disease. Here, an 
overview is given of results obtained by the use of molecular approaches to the 
identification of markers for prostate cancer development. 
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2. MOLECULAR CHANGES IN PROSTATE CANCER 
Tumor progression is associated with phenotypic changes, which are determined by the 
pattern of protein expression. Aberrant protein expression patterns that mark the 
progression, however, often find their origin in genomic alterations. Therefore, studies on 
the involvement of specific genetic changes, such as chromosomal abnormalities, can 
serve as a lead to identify genes that are implicated in the onset and progression of 
cancer. The molecular biology of human cancer has seen explosive progress in the last 
decade. Several cancer susceptibility genes have been identified and have provided a basis 
for the understanding of the relationship between inherited malignancies and sporadic 
forms of common human cancers. However, despite the high prevalence of prostate 
cancer, little is known with regard to the molecular pathogenesis of this disease. Several 
studies have focused on chromosomal loss, which might indicate areas of the genome that 
harbour important tumor suppressor genes. 
2.1 Genetic changes 
Until a few years ago, the genetic changes leading to the development and progression of 
prostate cancer were poorly characterized. Classical cytogenetic studies are difficult to 
carry out in prostate cancer due to the low mitotic index of prostatic tissue and to the 
preferential growth of non-malignant cells in tissue culture. Nonetheless, the involvement 
of some specific chromosomal changes has been identified: loss of chromosomes 1, 2, 5, 
11 and Y, trisomy of chromosomes 7, 14, 20 and 22 and structural changes involving 
chromosomal segments 2p, 7q and lOq were the most common changes reported (1). Of 
these, deletions of 7q and lOq were found in late-stage cancer. These findings, however, 
are all based on small numbers of patients. A less complicated technique that overcomes 
the previously mentioned problems with prostatic tissue is allelotyping. Using DNA 
probes that recognize Restriction Fragment Length Polymorphisms (RFLPs), one can 
identify deletions of parts of a chromosome. Allelic loss studies have been instrumental in 
the identification of putative tumor suppressor gene loci in a variety of cancers, for 
instance the frequent deletion of the long arm of chromosome 17 in colon cancer was 
revealed, leading to the identification of p53 as a potential tumor suppressor gene (2). 
Several allelotype analyses have been performed for prostate cancer: Carter and 
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collaborators (3) examined "loss of heterozygosity" (LOH) by means of RFLP analysis in 
28 prostate cancer specimen (most of them organ-confined, stage В lesions) using probes 
for 7q and lOq (until then reported as most frequently showing loss) as well as probes for 
chromosomes documented to harbour tumor suppressor genes. They reported frequent 
loss of lOq and 16q. Kunimi and colleagues (4) studied ten primary tumors and eight 
metastatic lesions and found, besides loss of chromosomes 10 and 16 also frequent loss of 
chromosome 8. Bergerheim and colleagues (5) extended this study in 18 prostate cancer 
specimen and demonstrated that the highest frequency of allelic loss was restricted to the 
short arm of chromosome 8. Frequent allelic loss of chromosome 8p has since then been 
confirmed by several other studies (6-8) and research is ongoing to identify and 
characterize the putative tumor suppressor gene, located on chromosome 8p, which is 
involved in prostate cancer development. Interestingly, chromosome 8p is also frequently 
lost in colorectal cancer (45%), non-small cell lung cancer (50%), hepatocellular 
carcinoma (45%) and bladder cancer (25%). Future studies will have to reveal whether 
the same gene is affected in these cancers. 
Whereas on 8p and lOq as yet no candidate tumor suppressor genes are mapped, an 
invasion suppressor gene, i.e. E-cadherin, is located on 16q22. Clearly, the relevant 
suppressor genes are candidates to be used as molecular markers of prostate cancer 
development and progression. 
2.2 Differential gene expression 
Another way to identify candidates for such analyses that are not directly implicated in 
molecular genetic alterations, such as mutational activation or inactivation, is to identify 
genes that are differentially expressed. Differential and subtraction hybridization analysis 
provide a direct approach to identify genes that are expressed at different levels in the 
tissues studied, being based on comparison of "steady state" mRNA populations. 
Differential or subtraction hybridization offers several possibilities: one can screen for 
genes which are up-regulated (e.g., genes that are overexpressed as a result of, for 
instance, gene amplification or oncogene activation) as well as for genes which are down-
regulated (e.g., genes that are no longer expressed, due to allelic loss, or transcriptional 
down-regulation/inactivation). Furthermore, the reagents that become available, i.e., 
cDNA clones, are easy to characterize by DNA sequence analysis and can be tested for 
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usefulness in the diagnosis by Northern blot analysis or RNA in situ hybridization 
(RISH). Differential and subtraction hybridization have been successfully applied, to 
identify genes differentially expressed when comparing normal to malignant tissue. For 
prostate cancer, differential hybridization was used to study general changes in gene 
expression. In our laboratory, we identified a number of cDNAs overexpressed in 
metastasizing rat prostatic cancers (9, 10, 11). One of those clones was shown to be 
identical to High Mobility Group protein I(Y) (10). HMG-I(Y) is a small non-histone 
nuclear protein implicated in transcription and replication processes. It's overexpression in 
dedifferentiated, fast-proliferating cells was reported earlier. The value of HMG-I(Y) as 
progression marker was further investigated by means of RNA in situ hybridization 
(12). This was done on paraffin-embedded tissue, thus enabling retrospective evaluation 
of the value of this marker. In the first evaluation it appeared that also in human prostate 
cancer HMG-I(Y) was overexpressed in high-grade lesions and was associated with the 
presence of metastases (12). 
Recently, the technique of differential display was developed and was proven to be a 
powerful tool to identify and clone differentially expressed genes (13). Differential display 
analysis has some major advantages over traditional differential or subtraction 
hybridization, in that (1) it allows simultaneous comparison of multiple RNA samples; (2) 
both up- and down-regulated expression of genes can be studied in one experiment; (3) it 
is less time-consuming; and (4) only small amounts of RNA are required for this 
technique, allowing the use of the sometimes rare and/or small human specimens. 
Differential display analysis is likely to reveal several new genes that are up- or down-
regulated in prostate cancer development. 
Recently, it has been shown that in addition to deletions, mutations and chromosomal 
translocations, alterations in DNA methylation can also affect gene expression. 
Hypermethylation of CpG islands (areas of the genome rich in the sequence CpG, 
associated with the 5' regulatory regions of genes) has been associated with gene 
inactivation. Lee and colleagues (14) studied the methylation of the regulatory sequences 
at the locus of the glutathione S-transferase gene-pi (GSTP1 - the protein encoded by this 
gene can catalyze the de-toxification of electrophilic carcinogens by conjugation with 
reduced glutathione) and found that hypermethylation occurred in 20 of 20 human 
prostatic tumors, but not in normal prostatic tissue or in benign hyperplasia of the 
prostate (BPH). A striking decrease of GSTP1 expression was found to accompany human 
13 
Molecular alterations in prostate cancer 
prostate carcinogenesis. This group further analyzed 91 prostatic carcinomas by staining 
with an anti-GSTPl antibody and they were unable to show GSTP1 expression in 88 of 
these cancer specimen, suggesting that (hyper)methylation of GSTP1 regulatory sequences 
leading to decreased GSTP1 expression may be one of the most common genetic 
alterations yet described for prostate cancer. 
2.3 Oncogenes and tumor suppressor gene involvement in prostate cancer 
For prostate cancer, studies have been carried out of typical tumor suppressor genes, such 
as the tumor suppressor genes p53, retinoblastoma (RB) and the oncogene ras, which are 
frequently affected in other solid tumors. With regard to the p53 gene, the frequency of 
mutations in primary prostate cancer is low in comparison with other common cancers. 
However, preliminary data from a number of laboratories suggest that bone metastatic 
deposits of prostate cancer may frequently exhibit mutant p53. This suggest that p53 
mutations are "late events" in the progression of prostate cancer (15, 16). Obviously, 
more studies are required to establish the role of p53 in (the progression of) this disease. 
For Rb, mutations have been found in a subset of prostatic adenocarcinomas, but also 
here, more studies are required. Concerning a role for ras gene mutations in prostate 
cancer, the data obtained in American patients show that activation of the ras oncogene 
via point mutations is not a common event in either the initiation or the progression of 
prostatic neoplasia (17). In contrast to this, two reports on ras gene mutations in 
Japanese patients with prostate cancer show a significant occurrence of ras mutations in 
both latent and clinically manifest disease (18, 19). This raises the question whether 
significant differences exist in the genetic events associated with the development of 
prostate cancer in American versus Japanese men. 
2.4 Prostate cancer susceptibility genes 
More recently it has become clear that, as in breast cancer, a subset of prostate cancer 
has a familial background. Therefore, linkage studies have been initiated in prostate 
cancer families in order to characterize the loci harbouring the susceptibility genes 
involved in hereditary forms of this common disease. From initial studies it has been 
reported (20) that the gene responsible for this predisposition may account for 9% of the 
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total cases of prostate cancer observed and for 45 % of the cases observed in men under 
55 years of age. 
It is anticipated that such a study will provide critical information regarding the genetic 
mechanisms not only in hereditary prostate cancer but also in the more common sporadic 
disease. 
3. MOLECULAR PROGNOSTIC FACTORS 
Despite the tremendous increase in our knowledge of the molecular basis of prostate 
cancer relative few reports are available on the value of these findings for molecular 
diagnostics. 
3.1 E-cadherin/alpha-catenin imiminohistochemistry 
One of the best-studied candidates is E-cadherin. This molecule mediates Ca2+-dependent 
cell-cell interactions and has been shown to play an important role in embryonic 
development and morphogenesis. In later stages, E-cadherin is specifically expressed in 
epithelial tissues. The functional importance of E-cadherin in preserving epithelial tissue 
integrity was demonstrated by using antibodies against E-cadherin, leading to dissociation 
of epithelial cell layers in cell culture and, more significantly, to an increased invasive 
potential of cells. Increased invasive behaviour can also be induced by introducing 
E-cadherin antisense DNA into cells. Conversely, introduction of E-cadherin cDNA, by 
means of transfection, into invasive cells resulted in differentiation of carcinomas. These 
studies provide evidence that E-cadherin can act as an invasion suppressor. Invasiveness 
may be acquired by down-regulation of E-cadherin at the DNA, RNA or protein level. In 
recent years various laboratories have studied the expression of E-cadherin in a great 
number of different human and animal cell lines and carcinomas and found a reduced 
expression of E-cadherin correlating with poor differentiation of human tumors suggesting 
an important role for E-cadherin in the maintenance of the differentiated phenotype of 
carcinomas (for a review, see reference 21). 
We first studied the expression of E-cadherin in a rat prostatic cancer model system (22) 
and we found that down regulation of E-cadherin mRNA expression was associated with 
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the invasive capacity of the sublines studied. We then assessed E-cadherin expression in 
human prostatic cancer specimens by immunohistochemical analysis. In these human 
cancer specimens a correlation with Gleason grade was found (23, 24). Moreover, within 
the Gleason score 6, 7 and 8, E-cadherin differentiated two types, i.e. normal staining 
pattern versus aberrant staining (heterogeneous or negative). A correlation with survival 
was strongly suggested from the limited follow-up of the patients (24). 
Not all types of adhesion deficiencies in invasive carcinomas are caused by decreased 
E-cadherin expression. Loss of E-cadherin function may also be due to loss of or reduced 
contact with the cytoskeleton. Interactions between the cytoskeleton and adhesion 
molecules have been shown to be essential for a variety of cellular functions, including 
cell-cell and cell-matrix interactions and cell motility. Normally, the highly conserved 
cytoplasmic domain of E-cadherin associates with three independent proteins, called 
α-, ß- and 7-catenin. Significant changes in the cadherin-catenin complex have been 
shown to disturb the junctional complex, thereby affecting the greater motility of invasive 
cells (21). Preliminary studies, using immunohistochemical analysis on human prostate 
cancer specimen, showed that a-catenin expression is often down-regulated in high-grade 
prostate cancer (R. Umbas and colleagues, personal communication). Furthermore, these 
studies indicate that a-catenin may provide additional prognostic information for prostate 
cancer. However, large prospective studies will have to reveal the clinical value of both 
E-cadherin and a-catenin as prognostic factors. It is interesting to notice that the a-
catenin gene maps to chromosome 5q, a chromosomal region that is also frequently lost 
in prostatic tumors (25%). 
3.2 Candidate progression markers for prostate cancer 
The detection of circulating tumor cells is based on advanced methodologies based on the 
polymerase chain reaction (PCR) and despite equivocal reports to date this may be an 
important addition in the accurate assessment of the stage of the disease. New candidate 
tissue markers are cathepsin D, plasminogen activators (uPA, tPA, PAI-1, uPA-R), 
bcl-2, and frequency of allelic loss. 
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3.3 Molecular diagnostics; perspectives 
It is clear that through elucidation of the molecular cascade that leads to prostate cancer 
the use of this information can lead to a better assessment of the biological potential of 
prostate tumors. 
The exact place of all these new markers in the diagnostic armamentarium can be 
determined only in well-controlled, prospective clinical evaluations, in which methods are 
standardized. The multifocality and heterogeneity that are so characteristic of prostate 
cancer will undoubtedly complicate interpretation, particularly for biopsy material. The 
intrinsic sampling artifact will often result in biopsies that are poorly representative of 
the entire malignant process, as mapped in the radical prostatectomy specimens. 
Ironically, therefore, the value of presurgical molecular diagnostic procedures will be 
critically dependent on the development of clinical imaging tools that allow the urologist 
adequately to biopsy the most malignant area in the prostate. 
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4. OUTLINE OF THIS THESIS 
In cancer diagnostics, the use of molecular tools is at the verge of entering the clinic. 
Despite the limitations that still exist, the clinical necessity cannot be ignored and every 
effort should be undertaken to determine the potential of molecular prognostic factors. 
Most candidates were revealed through molecular and genetic studies as described in this 
chapter for prostate cancer. A review on the molecular alterations in bladder cancer is 
presented as introduction to the thesis of Jacqueline Vet (June, 1996). 
In chapter II the method to study the value of HMG-I(Y) as prognostic marker for 
prostate cancer (RNA in situ hybridization) is described. A retrospective study is then 
presented in chapter III. Studies on the importance of the more recently identified pl6INK4 
are described in chapter IV. 
The potential of this gene for bladder cancer was suggested from the literature and an 
analysis of bladder tumors comprising both typical transitional cell carcinoma as they 
present in the major portion of the western population and Bilharziasis associated bladder 
cancer is presented in chapter V. Finally, the candidate oncogenes in the amplicon on 
chromosome l lql3 were studied in a series of bladder cancers, as described in 
chapter VI. 
18 
Chapter 1 
REFERENCES 
1 Brothman AR, Peehl DM, Patel AM, McNeal JE. Frequency and pattern of karyotypic abnormalities 
in human prostate cancer. Cancer Res 50 (1990) 3795-3803 
2 Baker SJ, Fearon ER, Nigro JM, Hamilton SR, Preisinger AC, Yessup JM, Van Tuinen Ρ, 
Letlbetter DH, Barker DF, Nakamura Y, Vogelstein В. Chromosome 17 deletions and p53 mutations 
in colorectal carcinomas. Science 244 (1989) 217-221 
3 Carter BS, Ewing CM, Ward WS, Treiger BF, Aalders TW, Schalken JA, Epstein JI, Isaacs WB. 
Allelic loss of chromosomes 16q and lOq in human prostate cancer. Proc Natl Acad Sci USA 87 
(1990) 8751-8755 
4 Kunimi K, Bergerheim USR, Larsson IL, Ekman P, Collins VP. Allelic loss of human prostatic 
adenocarcinoma. Genomics 11 (1991) 530-536 
5 Bergerheim USR, Kunimi K, Collins VP, Ekman P. Deletion mapping of chromosomes 8, 10 and 16 
in human prostatic carcinoma. Genes Chromosomes Cancer 3 (1991) 215-220 
6 Bova GS, Carter BS, Bussemakers MJG, Emi M, Fujiwara Y, Kyprianou Ν, Jacobs SC, Robinson JC, 
Epstein JI, Walsch PC, Isaacs WB. Homozygous deletion and frequent allelic loss of chromosome 
8p22 loci in human prostate cancer. Cancer Res 53 (1993) 3869-3873 
7 MacGrogan D, Levy A, Bostwick D, Wagner M, Wells D, Bookstein R. Loss of chromosomal arm 8p 
loci in prostate cancer: mapping by quantitative allelic loss. Genes Chromosomes Cancer 10 (1994) 
151-159 
8 Trapman J, Sleddens HF, Van der Weiden MM, Dinjeas WN, König JJ, Schroder FH, Faber PW, 
Bosman FT. Loss of heterozygosity of chromosome 8 microsatellite loci implicates a candidate tumor 
suppressor gene between the loci D8S87 and D8S133 in human prostate cancer. Cancer Res 54 (1994) 
6061-6064 
9 Schalken JA, Ebeling SB, Isaacs JT, Treiger B, Bussemakers MJG, De Jong MEM, Van de Ven 
WJM. Down modulation of fibronectin mRNA in metastasizing rat prostatic cancer cells revealed by 
differential hybridization analysis. Cancer Res 48 (1988) 2042-2048 
10 Bussemakers MJG, Van de Ven WJM, Debruyne FMJ, Schalken JA. Identification of high mobility 
group protein I(Y) as a potential marker for prostate cancer by differential hybridization analysis. 
Cancer Res 51 (1991)606-611 
11 Bussemakers MJG, Verhaegh GWCT, Van Bokhoven A, Debruyne FMJ, Schalken JA. Differential 
expression of vimentin in rat prostatic tumors. Bioch Biopliys Res Commun 182 (1992) 1254-1259 
12 Tamimi Y, Van der Poel HG, Denyn MM, Umbas R, Karthaus HF, Debruyne FMJ, Schalken, JA. 
Increased expression of high mobility group protein I(Y) in high-grade prostatic cancer determined by 
in situ hybridization. Cancer Res 53 (1993) 5512-5516 
13 Liang P, Pardee AB. Differential Display of eucaryotic messenger RNA by means of the polymerase 
chain reaction. Science 257 (1992) 967-971 
14 Lee WH, Morton RA, Epstein JI, Brooks JD, Campbell PA, Bova GS, Hsieh WS, Isaacs WB, 
Nelson WG. Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase 
gene accompanies human prostatic carcinogenesis. Proc Natl Acad Sci USA 91 (1994) 11733-11737 
19 
Molecular alterations in prostate cancer 
15 Bookstein R, MacGrogan D, Milsenbeck SG, Sharkey F, Allred DC. p53 is mutated in a subset of 
advanced-stage prostate cancer. Cancer Res 53 (1993) 3369-3373 
16 Dinjens WN, Van der Weiden MM, Schroeder FH, Bosman FT, Trapman J. Frequency and 
characterization of p53 mutations in primary and metastatic human prostate cancer. Int J Cancer 56 
(1994) 630-633 
17 Gumerlock PH, Poonamallee UR, Meyers FJ, Devere White RW. Activated ras alleles in human 
carcinoma of the prostate are rare. Cancer Res 51 (1991) 1632-1637 
18 Konishi N, Enomoto T, Buzard G, Ohshima M, Ward JM, Rice JM. K-ras activation and ras p21 
expression in latent prostatic carcinoma in Japanese men. Cancer 69 (1992) 2293-2299 
19 Anwar K, Nakakuki K, Shiraishi T, Naiki H, Yatani R, Inuzuka M. Presence of ras oncogene 
mutations and human papilloma virus DNA in human prostate carcinoma. Cancer Res 52 (1992) 5991-
5996 
20 Carter BS, Bova GS, Beaty TH, Steinberg GD, Childs В, Isaacs WB, Walsh PC. Hereditary prostate 
cancer: Epidemiology and clinical features. J Urol 150 (1993) 797-802 
21 Birchmeier W, Behrens J. Cadherin expression in carcinomas: role in formation of cell junctions and 
the prevention of invasiveness. Biochem Biophys Acta 1198 (1994) 11-26 
22 Bussemakers MJG, Van Moorselaar RJA, Giroldi LA, Ichikawa T, Isaacs JT, Takeichi M, Debruyne 
FMJ, Schalken JA. Decreased expression of E-cadherin in the progression of rat prostatic cancer. 
Cancer Res 52 (1992) 2916-2922 
23 Umbas R, Schalken JA, Aalders TW, Carter BS, Debruyne FMJ, Isaacs WB. Decreased expression of 
E-cadherin in high grade prostate cancer. Cancer Res 52 (1992) 5104-5109 
24 Umbas R, Isaacs WB, Bringuier PP, Schaafsma HE, Karthaus, HF, Oosterhof GO, Debruyne FMJ, 
Schalken JA. Decreased E-cadherin expression is associated with poor prognosis in patients with 
prostate cancer. Cancer Res 54 (1994) 3929-3933 
20 
Chapter Π 
INCREASED EXPRESSION OF HIGH MOBILITY GROUP PROTEIN I(Y) IN 
HIGH-GRADE PROSTATIC CANCER DETERMINED BY IN SITU 
HYBRIDIZATION 
Yahya Tamimi, Henk G. van der Pœl, Marie-Madeleine Denyn, Rainy Umbas, 
Herbert F. M. Karthaus, Frans M. J. Debruyne and Jack A. Schalken. 
Department of Urology/Urological Research Laboratory (YT,HGP,RU,FMJD,JAS), 
Department of Pathology (MMD), University Hospital Nijmegen, 
Nijmegen, The Netherlands and Department of Urology (HFMK), 
Canisius Wilhelmina Hospital, Nijmegen,The Netherlands. 
Cancer Research 53: 5512-5516 (1993) 
21 
HMGI(Y) expression in human prostate cancer 
SUMMARY 
In a previous study using the Dunning rat prostate cancer model, we found high mobility 
group protein I(Y) [HMG-I(Y)] to be overexpressed in metastatic tumor lines when 
compared to non-metastatic lines. Hence, overexpression of this 12-kDa non-histone 
chromosomal protein may be associated with tumor progression. Firstly, by Northern 
analysis we showed that HMG-I(Y) expression increases in high grade prostate tumors. 
These studies, however, required fresh material, and clinical follow-up was limited. To 
overcome this problem paraffin-embedded material must be made amenable for 
determination of HMG-I(Y) expression in retrospective studies. RNA in situ 
hybridization enables the evaluation of mRNA levels in such material. We studied tumors 
from 71 patients with prostate cancer. The microscopic analysis of each sample included: 
(a) hybridization on sections with sense HMG-I(Y) and (b) 28S rRNA probes (non-
specific signal); (c) hybridization with antisense 28S rRNA (RNA preservation); (d) 
hybridization with an antisense HMG-I(Y) probe (quantification of HMG-I(Y) mRNA in 
the expressing areas). Data were quantified using an image analysis system. High 
expression of HMG-I(Y) was observed in regions with high Gleason grade (4 and 5); 
whereas in lesions of Gleason grade 3, both weak and no expression was observed. In 
areas of grade 1 and 2, as well as in normal glands, low or no expression was found. We 
conclude that HMG-I(Y) expression assessed by RNA in situ hybridization is related to 
tumor differentiation in prostate cancer. These findings indicate that HMG-I(Y) 
expression may be a marker in prostate cancer diagnosis, and the possible clinical 
implication of expression of this gene in malignancy is discussed in this report. 
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INTRODUCTION 
Prostate cancer is now the second leading cause of cancer-related deaths in United States 
males. In men older than 50 years, 1 in 11 will be clinically diagnosed with prostatic 
cancer. More than one-third of these patients will die from their disease (1). In these 
patients the tumor can remain stable for years or clinically progress rapidly towards a 
life-threatening situation. Prognostic indicators for the diverse biological tumor behaviour 
are thus urgently needed. 
Investigations regarding the activation and/or inactivation of oncogenes (2-4), growth 
factors, and tumor suppressor genes (5-8) have not yet revealed consistent differences 
between the latent and aggressive prostate cancers (9). H-ras (2) and p53 (7) mutations, 
as well as loss of Rb expression (5), are found to be not a frequent step in the molecular 
cascade leading to prostate cancer progression. We have therefore tried to identify 
suitable progression markers and genetic changes associated with prostate cancer 
progression. One of the interesting findings from these investigations was the loss of 
E-cadherin function, which is associated with the progression of prostate cancer (10). 
Another potential progression marker was identified upon differential screening of 
metastatic versus non-metastatic Dunning sublines (i.e., MAT-Ly-Lu versus H 
tumor). Three clones showed overexpression in the metastatic rat prostatic tumors and the 
nucleotide sequence analysis indicated that one of the clones was identical to the high 
mobility group protein I(Y) |HMG-I(Y)] (11). High mobility group proteins I and Y are 
two isoforms of a non-histone nuclear DNA-binding protein and result from alternative 
splicing from a single functional gene (12). They are characterized by: a low molecular 
weight; high content of basic and acidic amino acids and specific binding to the minor 
groove of A:T rich sequences (13, 14) presumably in a way similar to that of antitumor 
and antiviral drugs (Netropsin, Distamicin) and the dye Hoechst 33258 (15, 16). They can 
also become phosphorylated by cdc2 kinase (17), which presumably modulates 
DNA-binding activity. It has been also shown that they are involved in the condensation 
of chromosomes during metaphase and in the maintenance of the undifferentiated state of 
chromatin (18-22). It is of particular interest that HMG-I(Y) overexpression was also 
found to be up-regulated in de-differentiated myeloid cells (23) and during neoplastic 
transformation (11, 18, 24, 25). In order to investigate the possibility of using HMG-I(Y) 
as a progression marker we anticipated immunohistochemical analysis. However, 
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probably due to low immunogenicity of the protein, as yet no routinely applicable 
antibody and protocols are available. We therefore studied HMG-I(Y) expression in 71 
prostate cancer specimens by RNA in situ Hybridization (RISH). Image analysis 
techniques were applied for quantitation of RNA expression, and the in situ 
hybridization results were compared with Gleason grade and stage. 
MATERIALS AND METHODS 
Specimens were obtained by transurethral resection of the prostate, lymphadenectomy, or 
radical prostatectomy. They were either snap frozen immediately after surgery or fixed in 
formalin and embedded in paraffin. 
Preparation of frozen sections 
Serial sections from the frozen tissues were cut on a cryostat at 8 μπι, mounted on poly-
L-lysine-coated slides, covered with Carbowax fixative (2% polyethylene glycol 1500 in 
50% ethanol), and heated in a microwave oven for 30 s. For the microwave fixation 
method, we used a household microwave oven with a maximum power of 750 W and a 
frequency of 2450 MHz (26, 27). The sections were rinsed twice for 1 min in PBS 
[PBS = 137 mM NaCl, 2.7 mM KCl, 8.1 mM Na2HP04, 1.5 mM KH2P04, pH 7], 
washed for 5 minutes in 0.1 M glycine/PBS, and incubated in 0.3% Triton X-100/PBS 
for 10 min. After rinsing for 1 min in PBS, sections were post-fixed in 
4% paraformaldehyde/PBS for 5 min, rinsed in PBS, and acetylated in freshly prepared 
0.25% acetic anhydride/0.1 M triethanolamine, pH 8, for 10 min (28). The slides were 
then finally dehydrated in gradually increasing concentrations of ethanol prior to 
hybridization. 
Preparation of paraffin-embedded material 
Four-μπι sections were mounted on acid-precleaned poly-L-lysine-coated microscope 
slides and heated overnight at 50°C. The sections were deparaffinized, rehydrated in PBS, 
and treated with proteinase К (10 /ig/ml) in 20 mM Tris-HCl, pH 7.5 - 5 mM EDTA for 
15 min at 37°C before a post-fixation procedure as described in "Preparation of frozen 
sections." 
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In Situ Hybridization 
Preparation of [^SJUTP-Iabeled RNA probe. 
A full length Human HMG-I(Y) complementary DNA (cloned in pBluescript) was kindly 
provided by Dr. G.J.M. Pruyn and Dr. P.C. Van der Vliet (University of Utrecht, 
Utrecht, The Netherlands). The plasmid was digested with EcoRV to generate a template 
for antisense transcription. Alternatively, digestion with BamHl resulted in a template for 
sense probe synthesis, used as a negative control. To test the preservation of RNA, we 
used a 28S rRNA-specific probe cloned in pGEM-II (Promega). [35SJUTP-labeled 
single-stranded RNA probes were prepared according to the method of Melton et al. 
(29, 30), degraded to an average length of 200 nucleotides by alkaline hydrolysis (31), 
precipitated in ethanol, and resuspended in 100 μλ lOmM Tris-HCl, pH 7.5 - 1 mM 
EDTA. The specific activity of the radiolabeled probes, aliquoted and stored at -80°C 
until use, was approximately 1 χ IO7 cpm/^g template DNA. Twenty-five μ\ of the 
hybridization buffer [50% deionized formamide-2x SSC-10% dextran sulphate-5x 
Denhardt's (50x Denhardt's = 5 g Ficoll 400, 5 g polyvinyl pyrrolidone and 5 g bovine 
serum albumin in 500 ml H2O)-10 mM dithiothreitol, and 1 mg/ml tRNA] was mixed 
with 2 χ 103 cpm of [35S]UTP-labeled probes and applied to the sections. After the 
sections were covered with coverslips, overnight hybridization was performed at 46°C. 
Coverslips were removed in 2x SSC at room temperature, washed at 46CC in decreasing 
concentrations of SSC (twice for 30 min 2x SSC, twice for 30 min lx SSC, twice for 30 
min 0.5x SSC). In order to reduce background due to nonspecific binding, 1 mM 
dithiothreitol, 1% thiosulphate, and 14 mM mercaptoethanol was added to the washing 
solutions. The sections were finally dehydrated, dried, and dipped in LM-1 film emulsion 
(Amersham, UK) for high resolution microautoradiography diluted 1:1 in Milli-Q water. 
After an exposure time of 5 days in tightly closed boxes at 4°C the microautoradiographs 
were developed in Kodak D-19 developer (4 min), washed in water (20 s), fixed in 24% 
thiosulphate (w/v, 4 min), rinsed in water, counterstained briefly (1 min) in haematoxylin 
and mounted in Permount medium before microscopic examination. 
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Preservation of RNA 
In order to judge RNA preservation, samples were hybridized with sense and antisense 
28S rRNA probes. Samples with poorly or no preserved RNA were rejected from the 
analysis; i.e., the number of grains after hybridization with rRNA sense probe had to 
exceed 10 times background. 
Quantitation by image analysis 
The image analysis system consisted of a video camera (MXR, HCS, Eindhoven, The 
Netherlands), mounted on a routine light microscope, and a personal computer (Compaq 
Deskpro 386s; Compaq, Houston, TX) equipped with a framegrabber board (VFG 
Visionplus-AT; Imaging Technology, Inc., Bedford, MA). The output image was 
presented on a video monitor (PVM 1442QM; Sony, Tokyo, Japan). Software was 
written in TIM-image analysis language (TEA, Dordrecht, The Netherlands) and 
consisted of the following elements. For each tumor area 10 images were recorded at x40 
magnification. A Laplace filter was applied for grain identification. The mean number of 
grains per image was calculated for each slide. From these data the following score for 
in situ staining could be derived. 
Score A = mRNAHMOI(Y+) - [nRNA,,^^ 
This calculates the expression of HMG-I(Y+) mRNA minus its negative control 
HMG-I(Y-). 
Statistical analysis 
For a comparison of the means corresponding to four groups (Benign, Gleason grade: 
1-2, 3, and 4-5, the analysis of variance (F test) was performed on the A score 
(see "Quantitation by image analysis"). 
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RESULTS 
In order to test the probes and protocols we used a prostate cancer cell line (PC3) 
expressing high levels of HMG-I(Y) and analyzed this by RISH for HMG-I(Y) 
expression. We found high levels of HMG-I(Y) in these cells with an almost negligible 
background signal (data not shown). In order to evaluate HMG-I(Y) expression in human 
prostate cancer samples we used material harvested and stored under optimal conditions 
for RNA preservation, (i.e., from our tissue bench, snap frozen specimens that were 
stored in liquid nitrogen). 
Expression of HMG-I(Y) determined by RISH in frozen sections. 
On basis of rRNA hybridization (rRNA+) 88% of the frozen samples showed preserved 
RNA and were investigated for the presence of HMG-I(Y) mRNA by RISH. Table 1 
summarizes the HMG-I(Y) expression illustrated as the mean ± sd of Score A values for 
the non-malignant (Score B), Gleason grade 1-2, 3, and 4-5 lesions respectively. In the 
non-malignant specimens that were tested the signals obtained after RISH did not exceed 
that of the background (Fig. 1, Α-D). We concluded that under these conditions 
HMG-I(Y) expression was below the detection limit of this technique. 
Table 1. HMG-I(Y) expression in prostate cancer determined by RISH on frozen sections. 
Differentiation No. of cases Mean of Score A ± sd 
Benign 3 ND 
Gg (1-2) 5 206 + 142 
Gg(3) 18 1142 ± 739 
Gg (4-5) 28 2249 ± 729 
HMG-I(Y) mRNA levels expressed as A score (see "MATERIALS AND METHODS") in non-malignant 
(Benign), Gleason grade (Gg) 1-2, Gleason grade 3, and Gleason grade 4-5 tumors. ND, not detectable. 
Gleason grade 1-2 tumors. Three of five Gleason grade 1-2 cases studied showed a 
signal just above the detection limit. This weak signal was specifically located in the 
tumor cells within the glands and the mean expression level was 206 ± 142. 
27 
HMGI(Y) expression in human prostate cancer 
ж "^ 
Figure 1. (A-L). Representative examples of RISH on non-malignant tissue (Α-D), and malignant specimens 
of Gleason grade 3 (Ε-H), and 4-5 (I-L). Frozen sections were hybridized with antisense rRNA (A, E, I). 
and sense rRNA (B, F. J) (to assess RNA preservation). The hybridization with antisense HMG-l(Y) (C, G, 
K). and the sense HMG-I(Y) (D. H. L) to evaluate HMG-l(Y) expression. 
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Gleason grade 3 tumors. This heterogeneous group comprised small, medium, and large 
glands, as well as single acini with moderate variation in size and shape and cribriform 
growth (32). A clear expression of HMG-I(Y) was found in all tumor areas as illustrated 
in Figure 1, E-Η. Eighteen samples were analyzed and HMG-I(Y) expression was 1142 
± 739. 
Gleason grade 4-5 and anaplastic tumors. In Gleason grade 4-5 tumors HMG-I(Y) 
RISH resulted in higher "grain density" when compared to Gleason grade 1-2 and 
Gleason grade 3 tumors (Fig. 1, I-L). The mean Score A value for this group was 2249 
± 729. 
Of 28 informative, poorly differentiated tumors (Gleason grade 4-5) with preserved RNA, 
HMG-I(Y) expression was higher in all but two samples where the signal was absent. 
Table 2 summarizes the statistical analysis of these data, and significance was found for 
difference in expression levels between all groups (see t and Ρ values in Table 2). These 
results indicate that HMG-I(Y) expression increases with grade (see Fig. 2). 
It would be extremely interesting to see how these results correlate with clinical follow 
up. Unfortunately, for prostate cancer the time required for such analysis is at least 10 
years hence, retrospective studies are required and the RISH technology should be 
applicable to archival, paraffin-embedded material. 
Table 2. Statistical analysis of combined RISH data of frozen and paraffin sections. 
Mean values of A ± sd t Ρ 
-4.4 <0.0001 
-8 <0.000l 
-5.5 <0.0001 
t test was performed to compare (2 χ 2) the groups for their HMG-I(Y) expression. 
Ggl-2 
Gg3 
Ggl-2 
Gg4-5 
Gg3 
Gg4-5 
198.4 ± 157 
1107 ± 685 
198.4 ± 157 
2293 ± 817 
1107 ± 685 
2293 ± 817 
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Figure 2. Correlation of HMG-I(Y) expression with Gleason grade in prostate cancer. Frozen material (•) 
and paraffin-embedded material (•). 
Expression of HMG-I(Y) determined by RISH in archival material. 
We therefore used RISH on archival formalin-fixed paraffin-embedded material. Among 
the samples taken for this purpose, 70% revealed RNA preservation and were analyzed 
for HMG-I(Y) expression by RISH. Table 3 summarizes the expression level for archival 
material samples, according to their score A values calculated by image analysis. As in 
case of frozen material, with non-malignant prostatic paraffin-embedded tissue, no 
HMG-I(Y) expression was found (Fig. 1С). 
Table 3. HMG-I(Y) expression in prostate cancer determined by RISH on paraffin-embedded material. 
Differentiation No. of cases Mean of Score A + sd 
Benign 
Gg (1-2) 
Gg(3) 
Gg (4-5) 
Meta 
4 
5 
4 
7 
10 
ND 
187.0 ± 157 
955.0 ± 419 
2454 i 1143 
1900 i 650 
HMG-I(Y) mRNA levels expressed as A score in non-malignant (Benign), Gleason grade (Gg) 1-2 
Gleason grade 3, and Gleason grade 4-5 tumors. ND, not detectable; Meta, metastasis. 
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Gleason grade 1-2 tumors. The weak signal observed in these tumors is, as in the frozen 
sections, located in the tumor cells. Three of the five cases studied had an HMG-l(Y) 
expression just above the detection limit and the mean expression value for this group was 
186 ± 157. 
Gleason grade 3 tumors. In the four samples studied, three showed clear HMG-I(Y) 
expression, whereas one case was just above the detection limit. The HMG-I(Y) 
expression is measured after image analysis (954 ± 419). The signal was specifically 
located in the tumor cell areas. 
Gleason grade 4-5 tumors. A high specific signal in tumor areas was found for this 
group. Seven samples were investigated and showed strong HMG-I(Y) expression on 
tumor tissue. The HMG-I(Y) expression obtained in this category was slightly higher than 
the one calculated for frozen sections (A =2453 ± 1143 (compare Table 1 and Table 3). 
Expression of HMG-I(Y) in lymph node metastasis. Ten lymph node metastasis with 
preserved RNA were investigated. All specimen were paraffin-embedded and fell within 
the Gleason grade 4-5 group. HMG-I(Y) was highly expressed (Score A=2000-2300 
grains) in all cases except one, i.e., A=260 grains. 
Comparison of RISH results on frozen and paraffin-embedded material revealed (in most 
cases) slightly lower A values in paraffin material. However this difference is not 
statistically significant. Thus, combining the RISH data from frozen and paraffin sections, 
it became clear that there is no major difference between frozen and paraffin material for 
RISH analysis. 
DISCUSSION 
In an attempt to identify molecular differences between aggressive and non-aggressive 
prostate cancer using Dunning R-3327 rat prostate cancer sublines as model, we found 
HMG-I(Y) to be overexpressed in highly metastatic sublines. 
To gain further insight in the potential use of this marker we measured HMG-I(Y) 
expression in human cancers using RNA in situ hybridization, and the resulting 
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microautoradiographic results were quantified by image analysis. 
In the non-malignant specimens no detectable expression of HMG-l(Y) was demonstrable. 
Interestingly in prostate cancer HMG-I(Y) expression, confined to the malignant prostatic 
structures, could be detected. Moreover, the level of expression correlated with the 
Gleason grade. This was found to be statistically significant. These results corroborate the 
hypothesis that HMG-I(Y) expression is related to differentiation. A particularly important 
aspect of this study is that not only fresh frozen tissue can be analyzed. In addition to the 
snap frozen tumor specimens, in which the minimum of mRNA degradation is to be 
expected, we also analyzed archival material. Similar results were obtained for paraffin-
embedded material. The slightly lower signal observed with the latter is probably due to 
the differences in the procedure prior to hybridization. Indeed, formalin-fixed paraffin-
embedded material required a rough pretreatment (i.e., proteinase K>20 μg/ml) to 
make the mRNA accessible to the probe. During this step partial loss of mRNA may 
occur. We observed that, in addition to tissue damage, increasing the proteinase К 
concentration from 20 μg/ml to 100 /¿g/ml resulted in a substantial decrease of the signal 
(data not shown) and an alteration of tissue morphology. Similar finding reported 
recently, signal reduction by RNase A pretreatment (33) and a replacement of the 
protease treatment by saponin, have been suggested to prevent such damage and mRNA 
loss (34). 
Having found that HMG-I(Y) expression levels correlated with tumor grade (see Fig. 1), 
it would be of even greater importance to evaluate the relation with the stage. In the 
group analyzed (53 patients) preliminary observations indicate that HMG-I(Y) expression 
over a score of 1300 was associated with high stage, i.e., 40% in Tl and T2 versus 
70% in T3 and T4 (see Table 4). In 6 of 23 (T3) and 5 of 13 (T4) cases, the HMG-I(Y) 
expression level was below 1300 despite their high tumor stage. However, these 
exceptional cases (11 cases) had undergone hormone therapy prior to surgery which 
presumably interferes with the results. Thus, these preliminary analysis of HMG-I(Y) 
expression and tumor stage indicate that HMG-I(Y) has potential usefulness as a 
progression marker, albeit that few number of patients have been analyzed at the moment. 
It is of importance to note that the protocol to analyze archival material can resolve this 
matter in extensive retrospective studies, in which complete follow-up data can be 
included. 
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Table 4 Relationship between HMG-I(Y) 
Tl 
A < 1300 3 
A > 1300 1 
expression levels and 
T2 
7 
6 
stages 
T3 
6 
17 
T4 
5 
8 
Correlation between stage and HMG-I(Y) expression over and below a threshold of 1300 (A score) 
The mechanism that leads to increased HMG-I(Y) expression is unclear. Even more the 
mechanism by which HMG-I(Y) may interact with other factors in carcinogenesis is not 
yet understood However, all these divergent functions attributed to HMG-I(Y) thus far 
can be explained by the assumption that the protein alters the structure of naked DNA or 
chromatin, allowing and/or facilitating the binding of other proteins It has been recently 
shown that transcription factor NF-κΒ cannot activate transcription from its binding site 
PRDII unless an additional factor, which was identified as HMG-I(Y), was present (35) 
This synergistic effect is due to the interaction of HMG-I(Y) with A:T-nch sequence of 
PRDII through contacts in the minor groove, while NF-/cB interacts with GC-nch 
sequences at the two ends of PRDII through contacts in the major groove. Moreover, the 
fact that p50 and p65 subunits of NF-κΒ are members of the rel gene family, may allow 
speculations about the indirect implication of HMG-I(Y) in cancer via oncogenes. 
It has been also reported that HMG-I(Y) transcripts are highly expressed in fast 
proliferating undifferentiated cells (24), and it is related to a highly malignant phenotype 
rather than to neoplastic transformation (18, 36). Moreover, in the Dunning model 
system, HMG-I(Y) expression was specifically correlated with metastatic capacity and not 
with tumor-doubling time (11, 20) Similar findings were reported by Ram et al, (25) 
in mammary carcinogenesis. This study supports the previous data and, as in the Dunning 
R3327 rat prostate cancer model (11) and human cancer cell lines (1, 5, 6, 7, 14), 
HMG-I(Y) mRNA is increased in high grade malignant prostatic lesions. This is the first 
report on increased HMG-I(Y) expression in human cancers, i.e., in prostate cancer 
The limited retrospective study performed in this report, however, does not allow definite 
conclusions concerning the clinical usefulness of HMG-I(Y) as a prognostic marker A 
large scale study on archival material, together with a correlation analysis of HMG-I(Y) 
with survival will be necessary before an accurate assessment of the role of HMG-I(Y) as 
a potential marker in prostate cancer can be made. 
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SUMMARY 
In a previous study using RNA in situ hybridization (RISH), we found a significant 
correlation between high mobility group protein I(Y), [HMG-I(Y)] mRNA expression and 
tumor stage and grade in prostate cancer patients, suggesting that HMG-I(Y) might be a 
potential prognostic marker in prostate cancer. However, our clinical follow-up was 
limited because cryopreserved material was used. Assessing the potential prognostic value 
of this molecule is of importance because the clinical course of prostate cancer patients 
remains unpredictable. Here we describe our results on paraffin-embedded archival 
material from a group of 102 patients undergoing radical prostatectomy. These were 
evaluated for the presence of HMG-I(Y) using (RISH) and a follow up of 12-92 months 
(average 53 months) was available. In 2 of 14 prostate cancers in which the predominant 
histological pattern was of Gleason grade 1-2, a high HMG-I(Y) expression was 
observed, whereas in 19 of 23 Gleason grade 3, and 34 of 35 Gleason grade 4-5 tumors, 
high HMG-I(Y) mRNA levels were detected (chi-square=38.78, P<0.0001). Moreover, 
of tumors that expressed high HMG-I(Y) levels, 25% were organ confined (Tl-2) in 
contrast to 74.5% of the invading tumors (T3, chi-square = 15.8, Ж0.001). Furthermore, 
87% of recurrent tumors showed high HMG-I(Y) expression. However, a multivariate 
regression analysis including Gleason grade, clinical tumor stage, HMG-I(Y) expression, 
and PSA levels showed Gleason grade as the most accurate predictor of progression. High 
HMG-I(Y) levels measured by RISH were indicative for a worse prognosis, albeit that 
additional value over the more subjective grading methods was not evident. 
Keywords: RNA in situ hybridization; high mobility group protein; archival material; 
radical prostatectomy; multivariate analysis; prognostic markers 
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INTRODUCTION 
Prostate cancer is the most common malignancy among males (1). Preventive screening 
programs reveal more organ-confined lesions, leading to an increase in the number of 
radical prostatectomies. However, this may not have a significant impact on overall 
survival as these tumors show a variable clinical course that cannot be predicted with the 
current available markers. Thus, patients with the same disease status may or may not 
progress (2, 3, 4) after radical prostatectomy. As cancer cells undergo aberrant patterns 
of differentiation, it is likely that their phenotype, including cellular components 
responsible for differentiation, might be modified. Several biological markers have been 
studied in prostate cancer, but their prognostic value is unknown. Some markers have 
been found to be associated with the onset of prostatic cancer, i.e., increased S-phase, 
and elevated transforming growth factor (TgF)/fl (5). Other investigators have shown a 
correlation between the high expression of Ki-67, proliferating cell nuclear antigen 
(PCNA), MIB-1, and recurrent or metastatic disease (6, 7). We and others have shown 
that loss of E-cadherin, a molecule involved in maintaining tissue integrity, is associated 
with progression in prostate cancer (8, 9). Furthermore, decreased E-cadherin 
immunoreactivity correlated not only with tumor grade and clinical stage but also with 
poor prognosis in patients with prostate cancer (9), identifying E-cadherin as a potential 
useful prognostic marker. 
We have recently identified High Mobility Group protein I(Y) [HMG-I(Y)1, as a putative 
progression marker for prostate cancer (10). HMG-I(Y) belongs to a family of 
chromosomal non-histone proteins that is composed primarily of the isoform proteins 
HMG-I and HMG-Y (11, 12) and the closely related HMGI-C (13). Members of the 
HMG-I(Y) family are distinguished from other groups of HMG proteins by their ability to 
specifically bind to the minor groove of A:T rich DNA sequences (14, 15) presumably 
similar to anti-tumor and anti-viral drugs (Netropsin, Distamicin) and the dye Hoechst 
33258 (16, 17). In addition to its involvement in chromosome condensation (18, 19), 
recent reports suggested another possible role of HMG-I(Y) as a transcription regulatory 
factor (20, 21). Moreover, the cell cycle dependent p34cdc2-like kinases phosphorylate the 
DNA-binding domains of HMG-I(Y) both in vitro and in vivo (22) which may serve 
as an important regulatory mechanism for DNA binding modulation (17). A striking 
correlation between elevated levels of HMG-I(Y) and both neoplastic cell transformation 
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(11, 23) and metastases (10, 24) has been found. In prostate cancer, we have shown 
significant correlation between HMG-I(Y) mRNA expression, Gleason grade, and clinical 
stage (25). This finding prompted us to further analyze this molecule for its value as 
progression marker. We report here on the retrospective study of HMG-I(Y) mRNA 
expression in 102 radical prostatectomy specimens. As in our previous study (25), image 
analysis techniques were applied to quantitate mRNA expression as detected by RISH. 
The results were compared to Gleason grade, clinical stage and, more importantly, to the 
recurrence of the disease. 
MATERIALS AND METHODS 
Specimens from 102 consecutive radical prostatectomies performed in our institutions 
from 1985 to 1992 were included in this study. Samples were fixed in formalin and 
embedded in paraffin A complete pathological examination was subsequently performed 
for each patient including pelvic lymph nodes. All the slides were reviewed by one of us 
(HGP) and, for each patient, a representative block was chosen for further analysis. In 
order to have accurate measurement of mRNA levels, paraffin-embedded tissue from the 
MAT-LyLu tumor, a metastatic subline of the Dunning rat prostatic cancer model system, 
was taken as an external reference. This allowed a good estimation of the technique's 
effectiveness. HMG-I(Y) is well conserved between species (85% homology between 
human and rat) and moderately expressed in MAT-LyLu. 
Preparation of paraffin sections. 
Serial sections from each paraffin-embedded block (each block corresponds to one patient) 
were cut at 4 μηι thickness, mounted on slides covered with a 2% tissue adhesive glue 
solution and placed on a heating plate overnight at 50°C. The sections were 
deparaffinized, rehydrated in phosphate-buffered saline (PBS) [PBS =137 mM NaCl, 2.7 
mM KCl, 8.1 mM Na2HP04, 1.5 mM KH2PO, pH 7], washed for 5 mm in 0.1 M 
glycine/PBS and incubated in 0.3% Triton X-100/PBS for 10 mm. After a short rinse in 
PBS, sections were treated with proteinase К (10 ¿ig/ml) in 20 mM Tns-HCl, pH 7 5, 5 
mM EDTA for 15 min, post fixed in 4% paraformaldehyde/PBS for 5 min, rinsed in PBS 
and acetylated in freshly prepared 0 25% acetic anhydnde/0.1 M triethanolamme, pH 8, 
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for 10 min (26). The slides were then finally dehydrated in gradually increasing 
concentrations of ethanol before hybridization. 
In situ hybridization. 
Preparation of [35S]UTP-labeled RNA probe, hybridization, washing conditions, and the 
preparation of microautographs were performed as described previously (25). 
Preservation of RNA. 
In order to judge RNA preservation, samples were hybridized with sense and antisense 
28S rRNA probes. The antisense rRNA probe signal had to exceed 10 times background 
to be considered for inclusion in the study. Samples with poorly or no preserved RNA 
(13%, 13 of 102) were rejected from the analysis. Moreover, samples presenting an 
experimental failure in the external reference (9%, 9 of 102), or lacking follow up (3%, 3 
of 102) were not studied. 
Quantitation by image analysis. 
The system consisted of a video camera (MXR, HCS, Eindhoven, The Netherlands) 
mounted on a routine light microscope, and a personal computer (Compaq Deskpro 386s, 
Compaq, Houston, TX) equipped with a framegrabber board (VFG Visionplus-AT, 
Imaging Technology Inc., Bedford, MA). The output image was presented on a video 
monitor (PVM 1442QM, Sony, Tokyo). Software was written in TIM-image analysis 
language (TEA, Dordrecht, The Netherlands). For each tumor area corresponding to 
highest Gleason grade, five images were randomly recorded at 40x magnification. A 
Laplace filter was applied for grain identification. The mean number of grains per image 
was calculated for each slide and the following score for in situ HMG-I(Y) mRNA 
estimation could be derived: 
Srorp A = m ' ^NA H M 0 . | ( Y X + ) - mRNAHM0. I (YX. ) 
mRNAref(+) - mRNAref(0 
This calculates the expression of HMG-I(Y)(+) mRNA normalized for an external 
reference. 
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Statistical analysis. For a comparison of the means corresponding to the four groups 
(Benign, Gleason grade: 1-2, 3, and 4-5), the analysis of variance (F test) was performed 
on the A score (see previous paragraph). The recurrence rate of patients that have higher 
or lower HMG-I(Y) mRNA expression compared with a determined threshold were 
evaluated according to Kaplan-Meier (27), and the differences between groups were 
performed using log-rank test. 
Threshold determination. 
Although the choice of a cut-off value is arbitrary, it should not desequilíbrate the groups 
in such a way that statistical methods are not applicable any more. The mean value ± (1 
or 2)x sd is the commonly used option in this particular case. We have chosen the mean 
value of Gleason grade 1-2 plus 1.5 sd = 0.65 as a cut-off value for this study. 
RESULTS 
In order to evaluate the potential prognostic value of HMG-I(Y) expression in prostate 
cancer by RISH, we used archival specimens obtained after radical prostatectomy. Tissues 
were fixed in formalin, embedded in paraffin and stored until use. 
Expression of HMG-I(Y) determined by RISH. 
By rRNA hybridization (rRNA+), 75% of the samples showed appropriate RNA 
preservation and were investigated for the presence of HMG-I(Y) mRNA by RISH. 
Table 1 summarizes the HMG-I(Y) expression as the mean A values + sd for the 
non-malignant tissue, and prostate tissue of Gleason grade 1-2, 3, and 4-5, respectively. 
In the non-malignant specimens the signals did not exceed background levels 
(Fig. 1, α-d). We concluded that under these conditions HMG-I(Y) expression was 
below the detection limit of this technique. 
Gleason grade 1-2 tumors. Fourteen cases of Gleason grade 1-2 (well-differentiated 
tumors) (28) showed clear expression of HMG-I(Y), specifically on cancer cells within 
the glands. The mean expression level was 0.42 ± 0.16. 
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Table 1. HMG-I(Y) expression in prostate cancer determined by RISH on paraffin-embedded tissue from 
patients who underwent radical prostatectomy. 
Differentiation Number of cases Mean of score A ± sd 
Benign 6 0.03 ± 0.04 
Gg(l-2) 14 0.42 ± 0.16 
Gg (3) 23 0.95 ± 0.38 
Gg (4-5) 35 1.34 ± 0.52 
HMG-I(Y) mRNA levels expressed as normalized A score (see "MATERIALS AND METHODS") in non-
malignant (Benign), Gleason grade (Gg) 1-2, Gleason grade 3, and Gleason grade (4-5) tumors. 
Gleason grade 3 tumors. Expression of HMG-I(Y) was detected in areas of the 23 
moderately differentiated tumors (Fig. 1, e-h). Two samples gave a lower signal similar 
to well differentiated tumors. The mean HMG-I(Y) expression was 0.95 ± 0.38. 
Gleason grade 4-5 tumors. Thirty-five samples of poorly differentiated tumors showed a 
strong signal specific to tumor cells. A higher grain density signal, was obtained in this 
category of tumors when compared with Gleason grade 1-2 and Gleason grade 3 tumors 
(Fig. 1, i-J). Table 2 summarizes our statistical analysis. Statistical significant 
differences in HMG-I(Y) expression levels between all groups were found (see t and Ρ 
values in Table 2). The analysis indicated that HMG-I(Y) expression increased with 
Gleason grade (see Fig. 2). 
Table 2. Statistical analysis of data obtained on paraffin-embedded tissue from patients who underwent 
radical prostatectomy. 
Group Mean values of A ± sd t value P-value 
Gg 1-2 0.42 ± 0.16 4.79 (< 0.0001) 
Gg 3 0.95 ± 0.38 
Gg 1-2 0.42 ± 0.16 6.03 (< 0.0001) 
Gg 4-5 1.34 ± 0.52 
Gg 3 0.95 ± 0.38 3.07 (= 0.0030) 
Gg 4-5 1.34 ± 0.52 
t test was performed to compare (two by two) the groups for their HMG-I(Y) expression. 
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h 9 
i t ,. 
Figure 1. (α-O, Representative examples of RISH original magnification (x40) on non-malignant tissue 
(α-d), and malignant specimens of Gleason grade 3 (e-h), and 4-5 (;'-/). Paraffin-embedded sections were 
hybridized with, antisense rRNA (a, e, i), sense rRNA (b, ƒ j) (to assess RNA preservation). The 
hybridization with antisense HMG-I(Y) (c, g, k), and the sense HMG-I(Y) (d, h. /) to evaluate HMG-I(Y) 
expression. 
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W G - K V l e c a r · 
Benign Gg 1-2 Gg 3 Gg 4 - 5 
Figure 2. Correlation of HMG-I(Y) expression with Gleason grade (Gg) in prostate cancer. 
Considering that increased expression of HMG-I(Y) might be associated with 
aggressiveness and invasiveness of tumors, we evaluated whether HMG-I(Y) expression 
(over the fixed threshold of 0.65) correlated with clinical stage. High HMG-I(Y) 
expression (A>0.65) was associated with high-stage disease., i.e., 25% in Tl + T2 
versus 91% in T3 and T4 (chi-square=15.8, />=0.001, see Table 3). 
Table 3. Relation between HMG-I(Y) expression levels and stages. 
Tl T2 T3 T4 
A < 0.65 13 
A > 0.65 13 40 
Correlation between stage and HMG-I(Y) expression over and below a threshold of 0.65 (normalized 
score A). 
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PSA levels and HMG-I(Y) expression correlation. 
In order to assess whether the disease had already spread outside the prostate after radical 
prostatectomy in those cases of high Gleason grade, we compared patient levels of PSA 
with the expression levels of HMG-I(Y). PSA was measured periodically (once per six 
months) during the follow up of the patients. Among 102 patients analyzed, PSA levels 
rise above 0.5 ng/ml in only 11 patients. Most of these high-level PSA patients are 
high-stage (ten patients pT3, one patient pT2) and high-grade (three patients Gleason 
grade 4, four patients Gleason grade 3, four patients Gleason grade 2) however, only five 
patients showed high HMG-I(Y) expression (A>0.65). A further regression analysis 
demonstrated that PSA level as measured after radical prostatectomy has no additional 
value in this study. 
Progression analysis. 
Follow up of patients ranged from 12 to 96 months. Forty-three percent (31 of 72) 
showed evidence of progression clinically or biochemically, i.e., PSA > 0.5 ng/ml 
(five cases). Most of these patients (90%, 28 of 31) showed high HMG-I(Y) expression in 
their tumor specimens (A>0.65), with the majority falling into clinical stage 3 disease 
(77.5%, 24 of 31). Kaplan-Meier analysis showed a significant correlation between 
HMG-I(Y) expression and progression (Fig. 3 log-rank test: chi-square=5.0175, 
P=0.025). 
DISCUSSION 
Increased HMG-I(Y) mRNA levels are often found in rapidly proliferating or 
undifferentiated cells and in various malignant tissues including prostate cancer (10, 11, 
14, 29). Furthermore, induction of differentiation results in the down-regulation of 
HMG-I(Y) mRNA expression, suggesting that HMG-I(Y) expression is associated with 
cellular differentiation (30). In a previous study we showed that in specimens of 
non-malignant prostate tissue, HMG-I(Y) expression was absent, whereas HMG-I(Y) 
expression was clearly detectable in prostate cancer cells (25). Moreover, a statistic 
significant correlation between the level of HMG-I(Y) expression and Gleason grade and 
stage was found (25). 
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Figure 3. Kaplan-Meier progression free rate related to HMG-I(Y) expression. Log rank 
test: chi-square= 5.017, P=0.025. 
The present data on archival specimens confirm our previous findings (Fig. 2) and 
corroborate the hypothesis that HMG-I(Y) expression is related to differentiation. Indeed, 
in well-differentiated tumors 14% (2 of 14 cases) showed low HMG-I(Y) expression, 
whereas 83% (19 of 23) of moderately differentiated and 97% (34 of 35) of poorly 
differentiated tumors showed high HMG-I(Y) expression (chi-square=38.78, /»<0.0001). 
This strong correlation between tumor grade and HMG-I(Y) expression, determined by 
RISH, suggests that this might be used as an additional prognostic indicator for prostate 
cancer. However, a multivariate regression analysis, which included Gleason grade, 
tumor stage, HMG-I(Y) expression, and PSA levels showed Gleason grade as the most 
accurate predictor of progression (chi-square=21.35, P<0.0001). In this study, high 
HMG-I(Y) levels as measured by RISH were indicative for a worse prognosis, although 
additional value over the more subjective grading methods was not evident. 
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We found that HMG-I(Y), as measured with image analysis, was highly expressed in 14 
of 27 cases of tumors (51%) that were organ confined (Tl-2) in contrast to 41 of 45 of 
tumor cases (91%) invading through the prostate capsule (T3-4). Thus, there seems to be 
a tend towards higher HMG-I(Y) levels in higher stage tumors, which might be a 
reflection of the higher numbers of biologically aggressive cells in the latter tumors. 
Furthermore, 28 of 31 patients (90%) that showed recurrence of disease showed high 
HMG-I(Y) expression (A > 0.65). This is in agreement with previous studies on mouse 
teratocarcinoma cells (30) and mouse neoplastic cells induced by different procedures 
(18). In the present study we show that patients with low HMG-I(Y) expression are at low 
risk of recurrence since only 3 of 17 (17.6%) relapsed. In contrast, patients with high 
HMG-I(Y) expression had a high frequency of recurrence 28 of 55 cases (51%). 
However, HMG-I(Y) expression was not indicative for progression in all cases: in three 
patients with low HMG-I(Y) expression (A <0.65), and low-stage disease (Tl one case, 
T2 two cases) relapses were observed. The reverse was also observed in two patients: low 
HMG-l(Y) was measured despite high Gleason grade and stage. Nevertheless, HMG-I(Y) 
expression might be predictive for the malignant potential of prostate cancer cells. 
The mechanism by which the HMG-I(Y) gene is regulated in prostate tissue remains to be 
elucidated. The proteins are present in abundance (105-106 molecules/cell), which 
indicates that they could be involved in the regulation of many genes, some of which 
might be involved in cell growth. Recently, Friedmann et al. localized the HMG-I(Y) 
gene to the short arm of chromosome 6 in a region where rearrangements, translocations 
and other abnormalities have been found in number of human cancers (31). 
HMG-I(Y) has been implicated in a number of functions: the subunits of NF-κΒ (p50 and 
p65), members of the oncogene rel family, can only activate transcription from their 
binding site PRDII when HMG-I(Y) is also bound (32), similar the E-selectin gene, 
encoding for endothelial cell adhesion proteins, can be activated only via interleukin-13 
(IL-13) and tumor necrosis factor-α (TNF-a) induction of NF-κΒ through HMG-I(Y) 
binding (33). HMG-I(Y) is involved in rescuing scaffold-associated regions (SARs), 
A:T rich sequences from histone HI-mediated repression, which fold the chromatin fibre 
into higher order structures (34). Finally HMG-I(Y) plays a role in the suppression of IL-
4 transcription in Τ lymphocytes (35), as well as in the stimulation of a specific isoform 
of the activating transcription factor 2 (ATF-21M) binding to interferon-jS (IFN-j8) (36). In 
view of the multifunctionality of HMG-I(Y) in mammalian cells, it is not surprising that 
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high HMG-I(Y) expression is important in cancer progression. The results presented here 
indicate that measurement of HMG-I(Y) levels in prostate cancer may be useful as 
prognostic marker. However, the technical difficulties of RISH should be taken into 
account for routine use. The development of less cumbersome techniques for HMG-I(Y) 
detection, i.e., immunohistology, is necessary before this can be implemented. 
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SUMMARY 
The Cyclin-dependent kinase-4 inhibitor gene (pl6INK4) has recently been mapped to 
chromosome 9p21. Homozygous deletions of this gene have been found at high frequency 
in cell lines derived from different types of tumors. These findings suggested therefore, 
that ріб""" is a tumor-suppressor gene involved in a wide variety of human cancers. To 
investigate the frequency of pió1""4 mutations/deletions in prostate cancer, we screened 20 
primary prostate tumors and four established cell lines by polymerase chain reaction 
(PCR) and single-strand conformation polymorphism (SSCP) analysis for exon 1 and exon 
2. In contrast to most previous reports, no homozygous deletions were found in prostate 
cancer cell lines, but one cell line (DU 145) has revealed a mutation at codon 76. Only 
two SSCP shifts were detected in primary tumors: one of them corresponds to a mutation 
at codon 55 and the other one probably corresponds to a polymorphism. These data 
suggest that mutation of the ріб"4*4 gene is not a frequent genetic alteration implicated in 
prostate cancer development. 
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INTRODUCTION 
Cyclin-dependent kinases (CDKs) are key enzymes in driving cells through the cell cycle 
into mitosis. Their activity is tightly controlled by phosphorylation and dephosphorylation 
of the CDK itself and association with regulatory subunits. Binding of a specific cyclin is 
a prerequisite for kinase activity. On the other hand, CDK inhibitory subunits have been 
recently described. p21 and p27 share a region of homology, and form with CDK and 
cyclins ternary complexes that can inhibit a variety of CDKs (1, 2). pió"™4 was the first 
identified member (3) of a growing family of proteins that specifically inhibit CDK4 and 
CDK6 (4, 5, 6). These two CDKs act together with cyclin D to control Rb 
phosphorylation and passage through the starting point of the cell cycle. This is a crucial 
step in controlling cell growth and perturbation of this pathway is thought to be 
implicated in carcinogenesis (4). Moreover, the gene encoding pl6INK4 protein, (pl6INK4/ 
CDKN/ MTS1) has been recently located in the chromosomal region 9p21, a critical area 
of allelic loss in a wide spectrum of human tumors (3, 4, 5). Interestingly, a high 
frequency of homozygous deletions in the pl6INK4 gene in cell lines derived from a variety 
of human tumors including bladder and kidney have been reported (4). The mutation rate 
found in cell lines could even rival that of the p53 tumor-suppressor gene. However, in 
primary tumors the rate of pl6INK4 mutations seems to be rather low and varies in a 
tumor-type dependent manner (7, 8, 9). 
Here we investigated the alterations of ріб"™4 in cell lines and primary tumors of the 
prostate using the polymerase chain reaction (PCR) and single-strand conformation 
polymorphism (SSCP) analysis. 
MATERIALS AND METHODS 
Patient samples, cell lines and DNA isolation 
Four established prostatic cell lines (PC3, DU145, TSUprl, LNCaP) were grown in 
RPMI medium containing 10% of fetal calf serum until they reach confluence. DNA was 
extracted according to Miller et al. (10). Twenty prostate cancer samples of various 
Gleason grades (Gg2-Gg5) were obtained by transurethral resection of the prostate, and 
then frozen in liquid nitrogen. Areas containing at least 70% of tumor cells as judged by 
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step sectioning, were subjected to DNA extraction (10). 
Polymerase chain reaction (PCR) 
We amplified exon 1 and exon 2 for the analysis of pl6INK4 gene alterations in prostate 
cancer. Primer sequences used for amplification were: 
5'-GAAGAAGAGGAGGGGCTG-3'and 5'-GCGCTACCTGATTCCAATTC-3' for exonl. 
Two overlapping primer sets were taken to cover the entire 500 bp long exon 2: 
5'-GCAGCACCACCAGCGTGTCC-3' and 5'-GGAAATTGGAAACTGGAAGC-3'; 
5'-TCTGTTCTCTCTGGCAGGTC-3' and S'-TCTGAGCTTTGGAAGCTCT-S'. 
Purified DNA (50 ng) was amplified in a total volume of 50 μΐ using 50 pmol of sense 
and antisense primers, 200 μΜ of each dNTP, lx amplification buffer (17 mM 
ammonium sulphate, 67 mM Tris pH 8.8, 2 mM magnesium chloride, 10 mM 
jö-mercaptoethanol, 6.7 μΜ EDTA), 2.5 mM magnesium chloride for exon 1, 1.5 mM 
magnesium chloride for exon 2 and 0.5 μ.1 (2.5 unit) of Tag polymerase (Perkin Elmer). 
Dimethyl sulphoxide (5%) was added for each DNA amplification reaction. For SSCP 
analysis 0.3 μΐ [a-32P]dATP (370 MBq ml', -110 TBq mmol"1) was added to the 
reaction. Forty cycles of 50 sec at 94°C, 40 sec at 61 °C, and 40 sec at 72°C were 
carried out in a Perkin-Elmer thermal cycler. The PCR products were subsequently 
analyzed by electrophoresis on 2% agarose gels. 
SSCP analysis 
The reaction product (3 μΐ) was mixed with 10 μΐ of loading buffer containing 96% 
formamid. Samples were denatured at 94°C for 3 min, chilled on ice for at least 5 min, 
and 2 μΙ was loaded onto a 6% non-denaturing Polyacrylamide gel with or without 10% 
glycerol. Gels were electrophoresed at 5 W (with glycerol) and 3 W (without glycerol) 
for 16 hours at room temperature, using 0.5x Tris-borate-EDTA buffer. Gels were dried 
and exposed to Amersham film (RPN8 35x43 cm) at -80°C for 3 days. 
Sequence analysis 
PCR products displaying a shift on SSCP analysis were sequenced both directly, as 
described before (11) and after being cloned into a TA cloning vector (pCRII; Invitrogen, 
San Diego, CA). 
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RESULTS AND DISCUSSION 
We have studied the mutation frequency in the pl6INK4/MTSl gene, in prostate cancer. 
Exon 1 and exon 2 represent the major part of the coding sequence (98% of the ріб04*4 
protein), whereas exon 3 makes up only 11 coding nucleotides (2% of the total coding 
sequence). Amplification of tumor genomic DNA using primers for exon 1 and exon 2 of 
the pió"4"4 gene resulted in bands of the predicted size 350, 240, and 340 bp respectively 
when separated on 2% agarose gel. A PCR product of the expected size was obtained in 
each of the four prostatic cell lines, indicating that none of them has a homozygous 
deletion of the ріб11™4 gene. 
We subsequently investigated the presence of point mutations in exon 1 and exon 2 
fragments of pió"*144 gene by SSCP analysis, a technique that is sensitive enough to detect 
more than 80% of mutations (12). The screening of almost the entire coding sequence 
(98%) of ріб1™4 revealed band migration shifts, for exon 2, in one cell line (DU 145) and 
two primary tumors (see example in Fig. 1, sample 21). 
The corresponding PCR products were sequenced. This revealed a missense mutation in 
DU145 at codon 76 (GAC -» TAC) resulting in a change from aspartic acid to tyrosine 
(see example in Fig. 2). The shift found in one of the primary tumors (case 166) was a 
mutation at codon 55 (CTG -* CCG) leading to a change from leucine to proline. It 
remains to be determined whether the substitution of the Asp with Tyr and Leu with Pro 
at codons 76 and 55 respectively plays a part in prostate cancer development. The shift in 
the other primary tumor (case 154) corresponded to a GCG-»ACG transition at codon 140 
leading to a change from alanine to threonine. This change was previously reported and is 
thought to represent a polymorphism as it has also been found in white blood cells (9). 
Genetic aberrations involved in prostate cancer have been taken into consideration 
previously and partly studied. Likewise, loss of heterozygosity (LOH) studies, identifying 
chromosomal regions harbouring potential tumor-suppressor genes, have mainly revealed 
8p, lOq, 13q, 16q, and 18q (13, 14, 15). However, most LOH studies are limited to the 
analysis of a few chromosomes leaving the major part of the genome un-examined. 
Recently, genetic changes in primary and recurrent prostate cancer were analyzed by 
comparative genomic hybridization (CGH) (16), a new technique enabling the survey of 
the entire genome for gains and losses of DNA sequences (17). Losses most often 
involved 8p (32%), 13q (32%), 6q (22%), 16q (19%), 18q (19%), and 9p (16%) (16). 
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Figure 1. A representative example of SSCP analysis of the pl6 I N K 4 gene (exon 2) in primary tumors and 
established cell lines of the prostate. A migration shift displayed by one primary tumor (sample 21) is 
indicated by an arrow. 
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Figure 2. A representation of DNA sequencing of the SSCP shift observed in prostate cancer cell line 
DU145. A base substitution from cytidine to adenosine in the non-coding strand is indicated by an arrow. 
This base substitution leads to a change from guanine to thymine at codon 76 and results in an amino-acid 
change from aspartic acid to tyrosine. 
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Hence, the frequency of 9p losses seems higher than the frequency of ріб"™4 mutations 
we found in this study, suggesting that another gene is the major target on 9p. 
At present, the role played by the pl6INK4 gene in human cancer remains controversial. 
For instance, in a recent study using primary tumors from a variety of organ types, which 
were previously shown to have loss of heterozygosity involving 9p21-p22, ріб"1™" 
mutations were found in less than 3% (8). Mutations within the non-coding region, 
rearrangement and down-regulation of pl6INK4 could play a role in the inactivation of this 
gene in some cases (18). Furthermore, mutations within the promoter region may alter the 
normal expression of pió"""4 gene, although this type of mutation has not been reported to 
be a predominant mechanism of gene inactivation in human cancer (8). 
Using SSCP-PCR analyses on four established prostatic cell lines and twenty primary 
tumors, we were not able to find more than two mutations: one in the DU 145 cell line, 
and one in primary tumors. These results indicate that mutation of the pl6INK4 gene is not 
a frequent genetic change in the formation of primary prostate cancer. Moreover, in 
contrast to several reports in which homozygous deletion in cultured cell lines can reach 
85% (4), homozygous deletions in established lines of prostate cancer were not found in 
the four analyzed cases. Parallel to our observations on primary prostatic tumors, analysis 
of tumors from several organs such as astrocytomas (19), breast (20), bladder (8, 9), 
lung, brain, and kidney tumors (8) revealed pió"4"4 mutations in only a small fraction of 
primary tumors. Alternatively, higher frequencies have been found in some tumor types: 
16% in head and neck squamous cell carcinoma and up to 51% in oesophageal squamous 
cell carcinomas have been detected recently (7). Therefore, the pl6INK4 gene has certainly 
a key role in certain cases, but not in all tumor types. 
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SUMMARY 
We have studied ріб"™4 mutation (by PCR-SSCP) and deletion (by Southern blotting 
and/or multiplex PCR) in a series of 47 Bilharziasis associated tumors and compared the 
results to those obtained on series of 17 established bladder cell lines and non-Bilharziasis 
associated bladder cancer as they present in The Netherlands. In cell lines we found 9 
homozygous deletions and 1 mutation (59% of ріб"**4 alteration in cell lines) whereas in 
cases from The Netherlands deletions were found in 4 of 22 samples (18%). No 
mutations were detected in the 46 samples screened. Interestingly, in Bilharziasis 
associated bladder cancer, deletions were present in 23 samples and mutations in a further 
2 cases (53% of р16ШК4 alteration in Bilharziasis associated bladder cancer). No 
correlation was found between pl6INK4 alteration and histo-pathological data. Likewise, 
the same frequency of alteration was found in tumors with different differentiation 
patterns (squamous, transitional or adenocarcinoma). 
Three conclusions can be drawn from our work: (1) pl6INK4 alterations are more frequent 
in cell lines than in primary tumors; (2) in primary bladder tumors (Bilharziasis 
associated or not) pió"4"4 deletions are much more frequent than pió"""4 mutations; (3) 
pl6INK4 alterations are more frequent in Bilharziasis associated bladder tumors than in 
other bladder tumors. This high frequency of deletion is not related to a specific 
histological type but to the specific etiology of these tumors. 
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INTRODUCTION 
Changes tn cell cycle control are thought to be critically associated with cancer 
development. The progression from the Gl to the M phase, is controlled by a family of 
enzymes called the cyclin-dependent kinases (CDKs) (for review see (1) and references 
there in). The phosphorylated down stream effectors, transduce the signal and lead 
ultimately to DNA synthesis and mitosis. The CDK activity is dependent on positive 
regulators called cyclins, and inhibited by a set of proteins termed cyclin-dependent 
kinase inhibitors. In addition, other kinases and phosphatases participate in the regulation 
of CDKs. Cyclins are low molecular weight proteins whose function is markedly 
modulated during different phases of the cell cycle. The role played by these proteins in 
human cancer has long remained elusive. However, the fact that in some parathyroid 
adenoma, the promoter region of the parathyroid hormone gene is fused to the gene 
encoding cyclin Dl, provided the first evidence that cyclins can be directly involved in 
cancer development. Subsequent analysis showed that cyclin Dl can substitute totally or 
partially for certain oncogenes in cellular transformation assay in various cancers and 
cyclin Dl has been found to be overexpressed in several cancers (1), including bladder 
(2). 
Seven cyclin-dependent kinase inhibitors have been characterized so far; p57, p2l, p27, 
pl9, pl8, ріб1™4 (also called CDKN2 and MTS1), and pl5. pl6INK4 binds specifically to 
CDK4 and CDK6 and inhibits these 2 kinases (3). Interestingly, cyclin Dl activates 
CDK4 and CDK6. Thus pl6INK4 is a specific regulator of cyclin Dl dependent kinases. It 
is thus likely that ріб""*4 alterations can also be involved in cancer development. 
Mutations in the ріб"™4 gene were revealed in cell lines. In 46% of 290 studied cell 
lines, the ріб 1 ^ 4 gene was found to be homozygously deleted (4,5). Moreover, ріб04*4 
has recently been mapped to 9p21, a region prone to loss of heterozygosity in bladder 
cancer. It has thus been hypothesized that ріб1""44 is the target gene in this region (6, 7). 
Bilharziasis is one of the most widespread disease related to parasitic infections and 
especially endemic in tropical and subtropical countries according to the statistical data 
from the World Health Organisation (WHO), 200 million infected peoples were recorded 
in 74 different countries (8). Egypt is considered to be a hyperendemic area with an 
overall prevalence rate of 50% and an early age of onset (8). Bilharziasis is often 
associated with bladder cancer which occurs with a frequency of 31% of total cancer 
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incidence in Egypt (9, 10). These tumors have a different etiology and histology than 
Transitional Cell Carcinoma (TCC) as found in western countries. It has recently been 
suggested however, that bladder tumors of both origin are sharing some molecular 
alterations - e.g. overexpression of EGFR and c-erbB-2 - but also that some alterations 
differ in respective to the etiology - e.g. frequent loss of retinoblastoma expression in 
bladder tumors found in western countries but not in Bilharziasis associated tumors (10). 
To determine whether pi б"™4 is differentially involved in these 2 types of bladder cancer, 
we studied pl6INK'' mutations and deletions in Bilharziasis associated tumors in comparison 
to established cell lines and bladder tumors from The Netherlands. 
MATERIALS AND METHODS 
In this report, we limited our analysis to exon 2 alterations in the ріб 1 ^ 4 gene. Exon 1 
and exon 3 were omitted since they cover only a minor part of the pl6INK4 gene (32%) 
and most mutations/deletions reported so far are clustered in exon 2 (4, 5). 
Cell lines and patient samples. 
The following bladder cancer cell lines coming from the Sloan-Kettering Cancer Center, 
New York, were used in this study: SCaBER, J82, VMCubl, VMCub2, МСиЬЗ, 
SW-800, SW-780, SW-1710, T24, RT4, RT112, 575A, 647V, 253J, SD, Jon and 5637. 
Cells were grown in RPMI medium containing 10% of fetal calf serum until they were 
subconfluent. 
Forty-six frozen tumor samples from The Netherlands were analyzed by SSCP. In none 
of these evidence for schistosomiasis infection was found. Two were Squamous Cell 
Carcinoma (SCC), both grade 2, stage 3. The other tumors were TCC: 22 were 
superficial and 22 invasive, 11 grade 1, 16 grade 2 and 17 grade 3. The 2 SCC and 20 
TCC (10 superficial and 10 invasive; 4 grade 1, 7 grade 2 and 9 grade 3) were also 
analyzed by Southern blot and multiplex PCR. DNA was extracted as previously 
described (2). Only samples with more than 75% tumor material were included. 
Forty-seven formalin fixed, paraffin embedded Bilharziasis associated tumors were 
analyzed by both SSCP and multiplex PCR. Twenty were SCC, 20 were TCC and 5 were 
adenocarcinomas. In 2 cases, pathological data was not available. Six tumors were 
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superficial and 39 invasive. Twelve were grade 1, 25 grade 2 and 8 grade 3. After 
microdissection, DNA was extracted according to Wright and Manos (11). 
Polymerase chain reaction (PCR). 
We used 2 sets of primers covering exon 2 : 
5'-GCAGCACCACCAGCGTGTCC-3' and 5'-GGAAATTGGAAACTGGAAGC-3'; 
5'-TCTGTTCTCTCTGGCAGGTC-3'
 a n ( J 5 . _ T C T G A G C T T T G G A A G C T C T _ 3 ' 
Fifty ng of purified DNA was amplified in a total volume of 50 μΐ using 50 pmol of sense 
and antisense primers, 200 μΜ of each dNTP, lx amplification buffer (50 mM KCl, 10 
mM Tris pH 8.3, 1.5 mM MgCl2), 0.5 μΙ (2.5 units) of Taq polymerase (Perkin Elmer, 
Branchburg, NJ) and 5% of dimethyl sulfoxyde. Forty cycles of 50 sec at 94°C, 40 sec at 
61 °C, and 40 sec at 72°C, were carried out. The PCR products were analyzed on 2% 
agarose gels. 
Single Strand Conformation Polymorphism (SSCP) analysis. 
PCR was carried out as described above except that 0.3 μΐ [a-32P]dATP (3000 Ci/mmol; 
Amersham, Buckinghamshire, UK) was added to the reaction. Three μΐ of the reaction 
product was mixed with 10 μΐ of loading buffer containing 96% formamid. Samples were 
denatured at 94°C for 3 min, chilled on ice for 5 min and 2 μΐ were loaded onto a 6% 
non-denaturing Polyacrylamide gel with and without 10% glycerol. Gels were 
electrophoresed at 5 W (with glycerol) and 3 W (without glycerol) for 16 hours at room 
temperature, using 0.5x Tris-borate-EDTA buffer (66 mM Tris-HCl, 22 mM Borate, 
1 mM EDTA). Gels were dried and films were exposed at -80 °C for 3 days. 
Sequence analysis. 
PCR products displaying a shift on SSCP gel were sequenced both directly, using the 
Ampli Cycle sequencing kit (Perkin Elmer, branchburg, NJ) and after being cloned into a 
TA cloning vector (pCR II; Invitrogen, San Diego, CA). Sequence comparison was based 
on the EMBL/Genbank database (ac. L27211). 
Southern Blotting. 
Ten μg of DNA was digested by £coRI (for cell lines) or Hiruflll (for primary tumors) 
restriction enzymes, separated on a 0.8% agarose gel, transferred onto Hybond N+ 
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(Amersham, Buckinghamshire, UK) according to the manufacturer's protocol and 
hybridized (as previously described(2), with a probe of 500 bp corresponding to the entire 
exon 2 PCR product. For loading control, bladder cancer blots were hybridized with the 
pHE 5.4 probe corresponding to the ETS oncogene which is located at llq23-24 (12). 
For the cell lines, the HPG Ca 2.1 probe (13), corresponding to human plakoglobin, 
localized on 17q21 (14) was used. 
Comparative multiplex PCR. 
Comparative multiplex PCR was performed essentially as described before (15). The 
primer pair for exon 2 and one control primer pair for a gene located on chromosome 9q, 
were mixed in a PCR reaction and amplified for 30 cycles (1 min 94°C, 1 min 56°C, 
1 min 72°C). The PCR products, were electrophoresed through a 2% agarose gel. After 
ethidium bromide staining, signals from pl6INK4 and the internal control were compared 
and homozygous deletions were scored if the p\6mK4 signal was missing or highly 
reduced. 
RESULTS 
pl6INK4 deletions and mutations in cell lines. 
In 9 of 17 (53%) cell lines, no amplification of exon 2 of the ріб"4*4 gene was possible, 
suggesting homozygous deletions. In order to confirm whether in samples with no PCR 
product, indeed the gene was homozygously deleted, Southern blot analysis was 
performed. No signal was obtained in 9 of the 17 cell lines subjected to this analysis, 
confirming the homozygous deletion (Fig 1). 
We subsequently investigated the presence of point mutations using Single Strand 
Conformation Polymorphism analysis which revealed two shifts. One of them (SCaBER) 
has already been reported (16). In the other (Jon) the sequence alteration at position 454 
(codon 138) does not lead to any amino-acid change (AGA -» AGG, Arg -> Arg). 
68 
Chapter V 
P16 
Pg -
4 3 kb 
- 23 kb 
9 10 11 12 13 14 15 16 
P16 - «• * * · 4 3 kb 
Pg - 23 kb 
Figure 1. Homozygous deletions of pl6 I N K 4 (exon 2) in bladder cell lines by Southern blotting. 647V (1), 
TSU (2) (prostatic cell line), VMCub2 (3), 5637 (4), МСиЬЗ (5), SW780 (6), RT4 (7), SCaBER (8), T24 
(9), 253J (10), SD (11), SW-800 (12), SW-1710 (13), RT42 (14), J82 (15), and 575A (16). Samples 3, 4, 
5, 6, 7, 10, 11, 12 and 14 show homozygous deletions. 
pl6INK4 deletions and mutations in bladder tumors from The Netherlands. 
In all these tumors, bands of the predicted size (250 and 340 base pairs) could be 
amplified by PCR. However, the presence of a low percentage (10-25%) of normal tissue 
prevents the identification of homozygous deletions. Therefore, DNA of 24 frozen 
samples were tested for homozygous deletions in Southern blot analysis. In four of the 22 
TCC samples (18%) ріб"™4 appeared to be homozygously deleted. Multiplex PCR on the 
same samples confirmed the deletion in 3 of these samples. Therefore, PCR is an 
appropiate method to measure pió"1*4 deletions, albeit that one tends to underestimate the 
frequency. Also in the two SCC samples no deletions were found. 
Band migration shifts, as revealed by SSCP analysis were not found in non-Bilharziasis 
associated bladder cancer. Thus we could not find evidence for ріб 1 ^ 4 mutation in these 
46 bladder tumors. 
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р16ШК4 deletions and mutations in Bilharziasis associated tumors. 
As shown in Fig 2, after comparative multiplex PCR the band specific for pl61NK4 was 
often of reduced intensity when compared to the control one. Indeed, homozygous 
deletion of the pl6INK4 gene was found in 23 of 47 (49%) of the Bilharziasis associated 
bladder carcinomas. 
Using SSCP analysis 3 band migration shifts in the coding region of ріб0™4 (exon 2) 
were found. In one case, the sequence alteration at position 442 (codon 134) does not lead 
to any amino-acid change (GCG -» GCA, Ala -» Ala). Unfortunately, in the other two 
tumors (Fig 3) the sequence alterations could not be determined. 
Together, 25 of 47 (53%) tumors have a р і б ^ 4 alteration. The distribution of these 
alterations among the different histological types of tumor is shown in table 1. No 
correlation was found between pl6INK4 alteration and either grade or stage. 
IT) 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
Figure 2. Multiplex PCR analysis of Bilharziasis associated bladder tumors: samples with reduced signal for 
the pl6INK4 specific primer set (upper band) have been considered as deleted (lanes 2, 4, 6, 8, 10, 11. 14 
and 15). The lower band is our internal control. 
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Table 1. pl6,NK4 status according to histological type in the Bilharziasis associated, non-Bilharziasis 
associated tumors and bladder cancer cell lines. 
Tumor type 
Bilharziasis 
associated tumors 
Non-Bilharziasis 
associated tumors 
Cell lines 
Histological 
type 
sec 
TCC 
Adenocarcinoma 
unknown 
TCC 
sec 
Homozygous 
deletions 
11/20 
9/20 
3/5 
0/2 
4/22 
0/2 
9/17 
Mutations 
0/20 
2/20 
0/5 
0/2 
0/22' 
0/2 
1/17 
% alterations 
55% 
53% 
60% 
09E 
18% 
0% 
59% 
Total % 
alterations 
53% 
18% 
59% 
1 2 3 4 5 1 2 3 4 5 6 
Figure 3. SSCP analysis of exon 2 of pl6,NK4 gene. The two migration shifts found in Bilharziasis 
associated tumors are shown. A: SSCP for the 5' part of pl6INK4 exon 2 with a shift in lane 3; B: SSCP for 
the 3' part of pl6INK4 exon 2 with a shift in lane 4. 
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DISCUSSION 
In this paper, we have studied ріб"4*4 gene alteration in a series of 47 Bilharziasis 
associated bladder tumors from Egypt, and compared the results with those obtained for a 
series of bladder tumors from The Netherlands. As samples from Egypt were paraffin-
embedded, deletions were detected by multiplex PCR. We first compared this technique 
with Southern blot and found no false positive but one false negative: only 3 of the 4 
deletions found by Southern blot could be detected by multiplex PCR. Thus, the 
frequency of deletion we report here is rather an underestimation than an overestimation. 
This was also noticed by others (7). The false negative is probably caused by 
amplification of the DNA from the normal tissue which is more abundant in the DNA 
extracted for Southern blot (up to 25% normal tissue as estimated by step section) than in 
DNA from paraffin-embedded material which was obtained after microdissection. Indeed, 
the results of multiplex PCR were much more clear cut for the Bilharziasis associated 
bladder tumors than for the non-Bilharziasis associated tumors. Another explanation can 
be that, to be sure that we were detecting partial deletion and not simple losses of 
chromosome 9, we choose our control PCR set on chromosome 9q, a region prone to loss 
of heterozygozity in TCC found in western countries but not in Bilharziasis associated 
bladder tumors (17). 
We think that the two tumors with a shift should be considered as mutated since the shift 
has been repeatedly found and since direct sequencing is less sensitive than SSCP (18). If 
these shifts were caused by a polymorphism, the variant sequences would have 
represented at least 50% of the DNA, which is well above the detection limit of direct 
sequencing. Conversely, a mutation can be present in only one part of the sample 
analyzed which makes it undetectable by direct sequencing. 
Whatever the real status of these two tumors, 3 conclusions can be drawn from our work: 
(1) ріб 0 * 4 alterations are more frequent in cell lines than in primary tumors; this has 
already been shown and discussed in detail by others (16). (2) in primary bladder tumors 
(Bilharziasis associated or not) pl6INK4 deletions are much more frequent than ріб""*4 
mutations. (3) pi б"4"4 alterations are more frequent in Bilharziasis associated bladder 
tumors than in other bladder tumor types. 
Numerous mechanisms have been proposed for the association of Bilharziasis and bladder 
cancer (19). One theory concerning the possible role of carcinogens is most likely the 
72 
Chapter V 
plausible mechanism of the carcinogenic process induced by Bilharziasis infection. The 
N-nitroso compounds, a potential group of carcinogens widely present in the environment 
and arising in urine of patients suffering from Bilharziasis infection, seems to be 
implicated in the initiation of bladder cancer (20). Furthermore, methylation in DNA of 
Bilharziasis infected human bladder tissue was detected (21). 
The fact that deletions occur more frequently than single mutations has already been 
noticed in some other tumor types such as brain tumors (22, 23, 24, 15), lung cancers 
(25) and mesothelioma (26). In bladder also the rate of homozygous deletions has been 
found higher than the rate of mutations. The data presented here on bladder cancer from 
The Netherlands are thus in agreement with the literature (6, 7) although the rate of 
homozygous deletion varies from one series to another: 3 of 22 in our study and 5 of 25 
in the study of Cairns et al. (6) but this frequency was estimated as 38% by 
Williamson et al. (7) who studied a large series of tumors (140 samples). The lower 
frequency we found cannot be explained by the low sensitivity of the PCR technique as 
proposed by Williamson (7), since we have also used Southern blot analysis. 
To explain the higher frequency of deletion, it has been proposed that inactivation of 
pió"™ alone does not provide a strong selective advantage and that deletion could lead to 
the inactivation of several genes (22). ρ 15 is of course an appealing candidate for 
co-inactivation with ріб"™4 since its gene lies immediately beside that of pl6INK4 and since 
both proteins have similar biochemical properties. However in bladder tumors, a number 
of deletions have been found which do not involve the ρ 15 gene, leading to the hypothesis 
that another gene, telomeric to pió""*4, is co-deleted (7). However, in some tumor types, 
e.g. SCC of the esophagus (27, 28, 29), pió"""4 is frequently inactivated by point 
mutation, thus it seems that the selective advantage provided by pió0,1*4 inactivation varies 
according to tissue types. 
Experimental evidence that pl6INK4 may play a role in tumor progression has emerged 
from studying both sporadic and familial malignancies. In familial melanoma, a locus 
responsible for the disease has been mapped by linkage analysis to 9p21, a region that 
harbours the р іб"" 4 gene as well (30, 31). Furthermore, an association between germline 
pl61NK4 mutation and familial melanoma was observed in some kindreds, suggesting the 
possibility to consider the pl6INK4 gene as an inherited melanoma susceptibility gene (33, 
33). In a recent report, Hussussian et al. demonstrated in 9/15 families with inherited 
melanoma linked to 9p21, six pl61NK4 mutations that co-segregate with the occurence of 
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melanoma (34). 
A somatic mutation (Pro-81-Leu) was also detected in this study, in a tumor from an 
individual who displays the (Arg-87-Pro) germline mutation (34). A similar study on 15 
Dutch families, revealed a 19 bp exon 2 deletion in 13 kindreds (35). Surprisingly, all the 
kindreds carry the same deletion, suggesting the common ancestry of the population. 
Alternatively, none of the previously described melanoma-associated mutations were 
found in a study realized on 17 Australian melanoma kindreds, but one family carries an 
exon 1 mutation not described so far. This was shown to co-segregate with melanoma and 
cause an amino-acid substitution (Arg-24-Pro) (36). 
Sporadic cutaneous melanoma accounts for approximately 90% of all cases of melanoma 
and probably arises as an accumulation result of genetic defects (37). In a melanoma cell 
line established from an individual patient, it has been shown that deletion of 9p21 can 
occur before metastasis in sporadic melanoma (38). 
The most interesting finding of our study is the higher deletion rate in tumors from 
Egypt. In non-small cell lung cancer, it has been suggested that ріб""*4 alteration is a late 
event of the carcinogenic process (39). If this is also true for bladder, this could 
contribute to the higher frequency of alteration found in Bilharziasis associated bladder 
tumors, as they are generally detected at a more advanced stage. However we do not 
favor this hypothesis since we could not show an increased frequency of alteration with 
either grade or stage in these samples. Thus it seems that the increased frequency of 
pl6 ,NK4 alteration is truly associated with schistosome infestation. Actually, while this 
work was in progress, a study of genetic alterations found in SCC was published (17). 
They found pl6INK4 alterations in 6 of the 9 SCC from Egypt they have analyzed. The 
results we have obtained on a larger series confirm the high prevalence of pl6INK* 
alterations in Bilharziasis associated bladder tumors. However, Gonzalez-Zulueta et al. 
(17) suggest that pl6INK4 deletions would be a part of a pathway specific for SCC 
development. Indeed they have also analyzed 3 SCC from Sweden and found pl6INK4 
alteration in 2 of them. Our data do not support this hypothesis since: (1) the 2 SCC from 
The Netherlands we have analyzed show no pió01*4 alteration; (2) in Bilharziasis 
associated bladder tumors ріб"4*4 alterations were not restricted to SCC but found with a 
similar frequency in any type of tumors. Thus, according to our results, pl6 ,NK4 alteration 
is more associated with a specific etiology (the presence of schistosome eggs in the 
bladder wall) than with a specific histological type. 
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Since D type cyclin, CDK4, ріб""" and the retinoblastoma protein are acting in the same 
pathway, it has been proposed that inactivation or activation of one of these elements will 
deregulate the Gl transition. Indeed, aberrations of pl6INK4 and retinoblastoma occur in 
distinct subsets of cell lines (40). The fact that in Bilharziasis associated bladder tumors 
retinoblastoma expression is often conserved whereas pió"410* is often inactivated, supports 
this hypothesis. Also the study of bladder cancer samples from The Netherlands, which 
we analyzed for activation of cyclin Dl and inactivation of ріб"41" and retinoblastoma 
provided indications for this hypothesis (2). 
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SUMMARY 
l lql3 amplifications have been found in several cancers, including bladder tumors. 
However, the biological significance of this genetic alteration is not yet fully understood. 
To get more insight into the role of l lq l3 amplification in bladder tumor development, 
we have studied the level of amplification and expression of 4 (proto-onco) genes lying 
within the amplicon: cyclin Dl, FGF3, FGF4 and EMS1. DNA amplification was found 
in 5/46 tumors. There was no correlation between amplification and clinico-pathological 
data. No expression of FGF3 and FGF4 was detected whereas both cyclin Dl and EMS1 
were expressed at higher level in tumors with amplifications. Thus cyclin Dl and EMS1, 
but not FGF3 and FGF4, are likely to play a pathogenic role in the l lql3 amplification 
in bladder cancer. 
However, amplification is not the unique way of activation of these genes. Indeed, in 
situ hybridization and Northern blot analysis have shown that most bladder tumors have 
a fair to high expression of cyclin Dl and EMS1 in contrast to normal urothelium with a 
moderate expression. Interestingly, a trend towards higher expression occurs in superficial 
versus invasive tumors (8.8 ± 2.0 versus 1.9 ± 0.4; P=13% for cyclin Dl and 4.5 
± 1.4 versus 2.0 ± 0.4; P=8% for EMS1). Moreover, the 9 tumors with low 
expression are all highly malignant, leading to the hypothesis that the tumors developing 
through a cyclin D1/EMS1 independent pathway are more aggressive. 
Keywords: Cortactin; Cyclin Dl; EMS1; Amplification 
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INTRODUCTION 
It is now generally recognized that cancer develops through accumulation of genetics 
changes. The identification of these changes and the determination of their role in tumor 
pathogenesis is of particular interest. Indeed, a better understanding of tumor pathogenesis 
should improve tumor management, enabling a subclassification based on pathogenic 
pathways and hopefully a better optimisation of the treatment. 
For bladder cancer, Southern blot analysis revealed that several chromosomal loci are 
altered: loss of heterozygosity has been found for chromosomes 9q, l ip , 17p, 8p and 4p 
in respectively 57%, 32%, 32%, 23% and 22% of the tumors (1) and amplifications have 
been found on chromosomes 17q (2) and l lql3 (3, 4, 5). However, these genetic changes 
often involve a large number of genes, whereas only few of them are important for cancer 
development. Most of the time, the relevant genes remain to be identified. 
Amplification of DNA markers within the band ql3 of chromosome 11 was initially 
observed in breast cancer by using probes for two proto-oncogenes of the FGF family: 
FGF3 (formerly intl) and FGF4 (formerly HSTF1). However neither of these genes is 
consistently expressed in tumors and cell lines with amplification of this region (reviewed 
in 6 and 7). Hence, it is assumed that these two proto-oncogenes do not confer a selective 
advantage to carcinomas with an l lql3 amplification. The expression of these genes is 
not documented in bladder tumors, however it seems likely that in these tumors also, 
overexpression of other genes should be the driving force for the selection of this 
amplification. Using differential screening of cDNA library, two genes that are 
overexpressed in squamous cell carcinomas with l lql3 amplification were identified (8). 
One of these is identical to the PRAD1 proto-oncogene and is now officially designated 
cyclin Dl or CCND1 (reviewed in 7). The other, EMS1, is the human homologue of 
chicken cortactin (9), a filamentous actin-binding protein located in the cell cortex, which 
is phosphorylated in cells stimulated by EGF, PDGF or transformed by pp60src (10, 11, 
12). 
Here, we report on the level of DNA amplification and/or of RNA expression of these 
four chromosome l lql3 genes (FGF3, FGF4, cyclin Dl and EMS1) in a series of 46 
bladder tumors. We also analyzed the relationship between tumor aggressiveness and 
cyclin D1/EMS1 expression. 
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MATERIALS AND METHODS 
Twenty-three snap frozen superficial carcinomas (pTa-pTl) and 25 invasive carcinomas 
(pT>2) have been analyzed. Superficial tumors comprised two recurrences of previously 
analyzed tumors. Among the invasive tumors, two were squamous cell carcinomas. All 
the other tumors were transitional cell carcinomas. Pathological data are summarized in 
Table 1: the grading and the staging of the tumors were based on the WHO classification 
(13) and the TNM classification (14), respectively. As normal control, four cystectomy 
specimens from patients with non-urothelial tumors and five ureters from renal cell 
carcinoma patients were used. 
Nucleic acids have been extracted from step sectioned frozen tumors, and only samples 
with more than 75% tumor cells were included. 
DNA was extracted according to Miller et al. (15) and digested with Taq\ or Hindlll. 
Ten μg of DNA were electrophoresed through a 0.8% agarose gel and blotted onto 
Hybond N+ (Amersham) according to the manufacturer's instructions. 
RNA was extracted according to Auffray and Rougeon (16). Ten μ% of RNA were 
electrophoresed through a 1 % agarose gel after denaturation with glyoxal and blotted onto 
Hybond N+ (Amersham) according to the manufacturer's instructions. 
The following probes have been used: U21B31 for cyclin Dl (8), U21C8 for EMS1 (8), 
BK4 for FGF3 (17), pORFl for FGF4 (18), pHE 5.4 for ETS (19), PV962 for 
E-cadherin (20), /3-actin (a kind gift of Dr Bloemendal, Nijmegen) and a 28S ribosomal 
RNA (a kind gift of Dr Dorser, Nijmegen). Probes were labeled with |32PJdATP by 
random priming and hybridized overnight in 250 mM Na2HP04 pH 7.2, 1 mM EDTA, 
1% BSA, 7% SDS at 65°C. Blots were then washed at 65°C successively in 250 mM 
Na2HP04 pH 7.2, 1 mM EDTA, 1% SDS; in 125 mM Na2HP04 pH 7.2, 1 mM EDTA, 
1% SDS; and in 50 mM Na2HP04 pH 7.2, 1 mM EDTA, 1 % SDS (21). 
Autoradiograms were quantified using an Gelscan XL (Pharmacia). For RNA blots, 
/3-actin signal was used as an internal control for loading. For Southern blots, ETS and 
E-cadherin signals were used as references. Only tumors with a more than twofold over-
representation of l lq l3 genes found on three different blots were considered as bearing 
an amplification. 
For in situ hybridization the probes were recloned in pGEM vectors and sense and 
antisense RNA probes were generated using T7 and SP6 RNA polymerase (Promega). 
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A ribosomal RNA probe was used as internal control for RNA preservation. In situ 
hybridization was performed as previously described and grains were quantified using 
computer assisted image analysis (22). Grain counts for a specific probe were rapported 
to the count for the reference probe (count for ribosomal RNA divided by 100). 
RESULTS 
Amplification of cyclin Dl, FGF3 and EMS1 genes 
Southern blot analysis was performed on 48 tumors coming from 46 patients. The signal 
intensity obtained with ETS (located on the long arm of chromosome 11 outside of the 
amplicon) was used as a reference to correct for unequal loading and/or aneuploidy. 
Amplification was assessed for cyclin Dl, FGF3 and EMS1. In six patients, 
over-representation of all three markers was found (Fig. 1 and Table 1). In two patients, 
Ampi 5 4 9 15 22 3» 5 3* 22 3 
Figure 1. Southern blots (HindUl digestion) showing the tumors where an amplification has been found. 
The signals obtained for cyclin Dl (probe U21B31), FGF3 (probe BK4) and EMS1 (probe U21C8) were 
compared to that of ETS (probe pH 5.4). Fold of amplification are the mean of three different blots. The 
asterisk denotes the tumor for which the over-representation of 1 lql3 genes is not found when E-cadherin is 
used as a reference. On the right: molecular weight markers (kbp). C: control DNA extracted from 
peripheral blood lymphocytes. 4r and 6r denote recurrences of tumors 4 and 6 respectively. Samples from 
patients 1 and 43 are present on two different blots. 
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Table 1. EMS1 and cyclin Dl expression and 1 lql3 amplification in bladder tumors. 
Cyclin Dl EMS1 Cyclin Dl FGF3 EMS1 
Patient Stage Grade mRNA mRNA amplification amplification amplification 
1 
2 
3 
4 
4 ree 
5 
6 
6 гее 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
1 
a 
1 
1 
a 
1 
a 
a-1 
1 
2-3 
1 
a 
a 
a-1 
1 
1 
1 
2 
3b 
a 
a-1 
2 
a 
4 
>2 
2 
2-3 
3 
>2 
4 
a 
a 
2 
a 
>2 
2 
2 
2 
2-3 
3 
>2 
>2 
>2 
3b 
2 
3 
a 
2-3 
2 
1-2 
2 + 
2b 
2-3 
2 
1-2 
1-2 
1 
2.SSC 
1 
12 
1 
1-2 
2 
2 
2 
2 
2 
2 
2 
2-3 
2-3 
3 
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'In this tumor, the over-representation of cyclin Dl, FGF3 and EMS1 is observed when ETS is used as a 
reference but not when E-cadherin is used as a reference, ree: recurrence, ssc: squamous cell carcinoma, 
ND: not done. Fold of amplifications are the mean of three different blots using ETS as a reference. mRNA 
levels are expressed in arbitrary units using 0-actin as a reference. 
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amplification (three to fivefold). Since the increased signal has been consistently found on 
at least 3 different blots, this denotes an actual over-representation of the genes lying 
within the amplicon. However, a loss of the telomeric part of the long arm of 
chromosome 11 surrounding the ETS1 gene could also account for a low copy number 
over-representation of the l lql3 genes. To clarify this issue, we compared the cyclin Dl, 
FGF3 and EMS1 signals with the one obtained with a probe for E-cadherin located on 
chromosome 16. None of these tumors shows loss of heterozygosity on chromosome 16q 
indicating a normal copy number of chromosome 16 (PPB, unpublished data). 
The over-representation of l lql3 genes was still evident in three tumors, however in one 
tumor (case #1) no confirmation of the over-representation was found. Thus in this case, 
loss of the ETS locus is more likely than l lql3 amplification. So, case ti\ was not 
considered as amplified. 
The two patients with two tumors available had amplification in both tumors. Since the 
recurrent tumor occurred in both cases very soon after the first resection, they likely arise 
from the remaining tumor and variations in the degree of amplification probably reflect 
tumor heterogeneity and/or the admixture of various amounts of normal tissue. 
No correlation has been found between amplification and clinico-pathological data (grade 
and stage). 
Levels of FGF3, FGF4, EMS1 and cyclin Dl mRNA 
Total RNA from 37 tumors was subjected to Northern blot analysis. The /3-actin signal 
was used as internal control for RNA loading. This analysis (Fig. 2 and Table 1) showed 
that tumors with DNA amplification have higher levels of mRNA for CCND1 and EMS1 
than tumors without amplification (Fig. 3 and Table 1). The mean level of cyclin Dl is 
11.3 ± 7.4 for tumors with amplification and 2.4 ± 0.3 for tumors without amplification 
(/•<0.002). For EMS1, levels of 10.5 ± 4.8 and 2.1 ± 0.3 have been found (/><0.001). 
These differences are highly significant. However, there is no strict correlation between 
the gene copy number and level of expression. For instance case #43 has a 40-fold cyclin 
Dl DNA amplification whereas the relative mRNA level is only 5.9; while case #4 has 
only 8 to 13 gene copies with the highest mRNA levels (25 to 55). 
In order to assess what in fact means overexpression, mRNA levels in tumor cells were 
compared to normal urothelium. Since normal urothelium contributes only for a minor 
part to the normal bladder wall, extracted RNA would be mainly representative for the 
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Figure 2. Northern blot illustrating the expression of cyclin Dl (probe U21B31) and EMSl (probe 
U21C8). Arrow heads indicate the position of ribosomal bands. /3-actin expression is shown as a loading 
control. The asterisk denotes the tumor for which the over-representation of l lq l3 genes is not found when 
E-cadherin is used as a reference. A431 is a human vulvar carcinoma cell line used as positive control (it is 
known to have a twofold amplification). NK: Normal Kidney. 
mRNA lerci! 
(arbitrary units) 
• amplif ication 
t-J no amplification 
EMS 1 Cyclin Dl 
Figure 3. EMSl and cyclin Dl mRNA levels according to 11q 13 amplification. Mean mRNA levels for 
tumors with amplification (dark grey bars) and without amplification (light grey bars) are represented with 
the corresponding standard error. 
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stromal components. We thus choose to perform in situ hybridization on 9 normal 
urothelia and 16 tumors. After quantification using computer assisted image analysis, 
expression levels of 32.2 ± 8.2 (EMS1) and 5.9 ± 3.9 (cyclin Dl) were found in normal 
urothelium, whereas tumors had levels of 76.3 ± 8.0 and 70.5 + 8.2 for EMS1 and 
cyclin Dl respectively. Thus, a low expression was found in normal urothelium (see also 
Fig. 4). This expression level is comparable to the level in tumors with the lowest 
expression (mRNA level below 1 arbitrary unit by Northern blot analysis). Hence, tumors 
with mRNA levels above 2 (by Northern blot) can be considered as tumors with clear 
overexpression. 
Comparison of Northern and Southern blot data revealed that all the tumors with 
amplification have a clear overexpression of EMS1. For cyclin Dl, all tumors but one 
with a threefold amplification (#44), have clear overexpression. This latter tumor has a 
clear overexpression of EMS1 only whereas both cyclin Dl and EMS1 are amplified to 
the same extent (threefold). With regard to cases without DNA amplification, 22 of 34 
have overexpression of one of these genes. In two cases (#15 and #20) the overexpression 
Figure 4. Expression of cyclin Dl (c,d) and cortactin (e,f) assessed by in situ hybridization in normal 
urothelium (a,c,e) and one transitional cell carcinoma (b,c!,f). Hybridization with a probe for ribosomal 
RNA (a,b) has been used as a control for RNA preservation in the sections. 
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is more pronounced for EMS1, whereas in five cases (#25, 26, 31, 32 and 38) the 
converse is observed. The other cases have similar levels of overexpression. Thus cyclin 
Dl and EMS1 up-regulation occurs frequently during urothelial carcinogenesis. 
Interestingly a trend toward a higher expression occurs in superficial versus invasive 
tumors; 8.8 ± 2.0 versus 1.9 ± 0.4; P«13% for cyclin Dl and 4.5 ± 1.4 versus 
2.0 ± 0.4; P » 8 % for EMS1. Moreover, the nine tumors with low expression of one of 
these genes (mRNA levels below 1 arbitrary unit, i.e. tumors #8, 17, 24, 25, 27, 33, 
35, 37, 46) are all very aggressive. 
In contrast, we were unable to detect any FGF3 or FGF4 transcripts in 18 bladder tumors 
analyzed, two of them having an amplification. In only one case, after long exposure a 
very faint 4.2 kb FGF3 transcript was detected (data not shown). As this tumor had no 
l lql3 amplification, our data show that there is no consistency in FGF3 and FGF4 
overexpression and amplification. 
DISCUSSION 
We have found an 11% (5/46) prevalence of l lql3 amplification in bladder tumors. This 
is in agreement with previous data for bladder tumors since frequencies of 5.5% (1/18) to 
20.6% (20/97) (3, 4, 5) were previously reported. Including this study 205 tumors have 
been analyzed and 29 cases with amplification have been found (an average of 14%). The 
here found lack of correlation between l lql3 amplification and clinico-pathological data 
in bladder tumors is also in agreement with another study (5). 
In order to gain more insight into the role of l lql3 amplification, we assayed the 
expression of genes possibly involved in oncogenesis and lying within the amplicon. 
FGF3 and FGF4 are not expressed in bladder tumors and thus are not the genes 
responsible for the selection of l lql3 amplification in urothelial tumors. On the other 
hand, both cyclin Dl and EMS1 are expressed in bladder tumors and show an enhanced 
expression in tumors with l lql3 amplification. Cyclin Dl has been extensively studied 
and is involved in regulation of the Gl/S transition of the cell cycle (reviewed in 7). 
Overexpression of cyclin Dl is an usual feature of tumors and cell lines with l lql3 
amplification. Expression in tumors with amplification and rearrangement, as well as 
transfection experiments (23, 24, 25) have proven the oncogenic potential of cyclin Dl. 
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However, tumors with amplification but without overexpression are repeatedly found (26, 
23, 27, 28, 29). This might indicate that other gene(s) can also play a part in the selective 
advantage conferred by this amplification. EMS1 is a good candidate for such a gene 
since it is found amplified and overexpressed in all tumors with a cyclin Dl amplification. 
Recently another gene, EXP1, which meets the same criteria, has been described (30). 
Definition of the role of each of these players and of the way they possibly interact await 
further analysis. However, cloning of the full length EMS1 (9) revealed that EMS1 
encodes the human cortactin. Cortactin has first been characterized as a substrate of the 
tyrosine kinase encoded by the src oncogene (10). Cortactin binds to F-actin (12). In 
non-transformed chicken embryo cells, it co-localizes with cortical actin whereas in their 
5/r-transformed counterpart it relocalizes to focal sites of membrane-substratum contact 
called podosomes (10). Interestingly, similar localizations have been found in breast 
cancer cell lines without and with an l lql3 amplification respectively (9). Thus cortactin 
might be involved in both remodelling of the cortical cytoskeleton and change in 
cell-substratum contacts which are important events in cell transformation. 
Tumors without amplification can have a low level of expression of cyclin Dl and EMS1, 
similar to those found in normal urothelium, but most tumors show a higher expression 
revealing that amplification is not the most prevalent mechanism leading to 
overexpression of these 2 genes. This has already been noticed for cyclin Dl in other 
tumor types (27) and cyclin Dl overexpression has also been described in colorectal 
carcinoma where no l lql3 amplification has been found so far (31). Transcriptional 
de-regulation and/or change in mRNA stability might explain the increased mRNA level 
found here. 
Interestingly, we found that low expression of cyclin Dl and/or EMS1 correlates with 
more aggressive tumors. This is in contrast with what is found in some other tumor types 
(28, 32) but in keeping with the physiological role of at least cyclin Dl (the role of EMS1 
is less well understood). Indeed, cyclin Dl acts at an early Gl checkpoint and probably 
transmits extra-cellular signals to the cell cycle machinery. Its involvement in 
carcinogenesis makes sense since neoplasia is characterized by autonomous cell growth. 
However, the hallmark of cancer is the acquisition of invasive and metastatic potentials, 
and no direct role for cyclin Dl can be foreseen in these processes. In this respect, it is 
interesting to notice that cyclin Dl is involved in the genesis of benign tumors (33) and 
that in the mouse skin carcinogenesis system, cyclin Dl overexpression is probably 
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related to the acquisition of autonomous growth by papilloma (34). In the case of bladder 
tumors with low cyclin Dl expression, the growth autonomy is probably provided by 
mechanisms independent of cyclin Dl. The extreme aggressiveness of these tumors leads 
us to hypothesize that these mechanisms have more pleiotropic effects and give rise to 
tumors which are prone to progress. Thus, as far as cyclin Dl and EMS1 are concerned, 
bladder tumor would develop according to at least three pathogenic pathways: (1) 
amplification and overexpression; (2) overexpression without amplification; (3) pathways 
not implying overexpression of these two genes. Since cyclin Dl is involved in the 
progression of the cell cycle through the Gl phase of the cell cycle it is tempting to 
speculate that targeting of other molecule(s) involved in the same biochemical pathway 
occurs in tumors with low cyclin Dl expression. As a matter of fact, we attempted to 
identify the defect occurring in these tumors (Chapter V, PPB unpublished results). The 
CDK inhibitor pl6"NK'1 was never found mutated (all tumors have been tested). It was 
found deleted in about 20% of all the bladder tumors we have tested (я=23) but in none 
of those with low cyclin Dl expression (n=4). The eight tumors with low cyclin Dl 
expression have been studied by Western blotting with an antibody against retinoblastoma 
together with eight tumors with cyclin Dl overexpression. Rb expression was 
undetectable in two tumors with low cyclin Dl expression and a weak signal (probably 
caused by the remaining normal tissue) was seen in two other ones. Hence, 
retinoblastoma is indeed altered in some of the tumors with low cyclin Dl expression. 
However, undetectable (one case) or weak (two cases) Rb expression were also found 
among the tumors with high cyclin Dl. Thus, we did not find in primary bladder tumors 
a straightforward relationship between cyclin Dl expression and retinoblastoma such as 
the one described in oesophageal tumors (35) or in cell lines derived from lung cancer 
(36). 
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As described in Chapter I, prostate cancer is one of the most frequently occurring 
urological tumors. Moreover, prostate cancer is the second leading cause of cancer related 
deaths in the western male population. Despite the tremendous effort undertaken, little is 
known about the genetic changes leading to the onset and progression of prostate and 
bladder cancer. With the development of molecular biological techniques, tools have been 
provided to try to gain more insight into the complex process of tumor development. 
Moreover, these techniques can not only help us to understand the mechanisms underlying 
the transition from a normal cell to a highly malignant tumor cell, but may also provide 
us with new diagnostic tools and/or identify new targets for therapy. 
Chapter II describes the application of RNA in situ hybridization (RISH) as a tool to 
evaluate the usefulness of HMG-I(Y) as progression marker. HMG-I(Y) is a high mobility 
group protein that was previously reported to be overexpressed in undifferentiated and 
highly proliferative cells. We analyzed a group of 71 patients with prostate cancer by 
RISH and the results were quantified by image analysis. In both benign prostatic 
hyperplasia and normal prostate, no HMG-I(Y) expression could be detected. Only in 
prostate cancer specimens, high HMG-I(Y) mRNA levels were observed. Interestingly a 
statistically significant correlation between the level of HMG-I(Y) expression and the 
Gleason grade / clinical stage was evident. Since limited follow-up data were available, 
no conclusion with respect to the value of HMG-I(Y) expression as prognostic marker 
could be drawn. Comparative evaluation of RISH analysis on frozen and paraffin sections 
indicated that the methodology was suitable for assessing archival material. Therefore, a 
large retrospective study correlating HMG-I(Y) expression levels with survival was 
performed and is the subject of chapter Ш. 
We analyzed a group of 102 radical prostatectomies for HMG-I(Y) expression by RISH 
and the results were quantified by image analysis. From the specimen analyzed, a follow 
up of 12-92 months (average 53 months) was available. A correlation between HMG-I(Y) 
expression levels and both Gleason grade and stage was confirmed. This was in 
agreement with the results described in chapter II. Moreover, a significant correlation 
between HMG-I(Y) expression and progression could be shown (chi-square=5.0175, 
P=0.Q25). This study revealed a direct relationship between HMG-I(Y) expression levels 
and time to progression. However, a multivariate regression analysis including Gleason 
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grade, tumor stage, HMG-I(Y) expression and PSA levels showed Gleason grade as the 
most accurate predictor of progression. Despite the fact that increased HMG-I(Y) 
expression levels are an indication of a worse prognosis, additional value over the more 
subjective grading methods was not demonstrated. 
Recently, several cell-cycle regulators, like cyclins, cyclin-dependent kinases and cyclin-
dependent kinase inhibitors have been identified and there are indications that these 
molecules play an important role in cancer development. In the second part of this thesis, 
studies aimed at the elucidation of a putative role of cyclin dependent kinase inhibitor 
pió""™" and cyclin Dl in prostate and bladder carcinogenesis are described. 
Cyclin dependent kinase-4 inhibitor gene, ріб"™4, has been mapped to chromosome 9p21, 
a hot spot for chromosomal loss in several human cancers. Homozygous deletion of this 
gene has been found at high frequency in cell lines derived from different types of tumors 
suggesting a role for pió"™4 as a tumor suppressor gene. In chapter IV we used PCR-
SSCP analysis to investigate the frequency of ріб"™4 mutations and/or deletions in 
prostate cancer. We screened 20 primary tumors and 4 established cell lines for mutations 
and/or deletions of exon 1 and exon 2 of the pió"™4 gene. In contrast to most previous 
reports, no homozygous deletions were found in prostate cancer cell lines. However, 
three SSCP shifts affecting exon 2 were detected: one in the human prostate cancer cell 
line DU145 corresponding to a mutation at codon 76, and two in primary tumors. One of 
these corresponds to a mutation at codon 55 (leucine to proline), whereas the second at 
codon 140 probably corresponds to a polymorphism. These data suggest that mutation 
and/or deletion of the pi б1™0* gene is not a frequent genetic alteration in prostate cancer. 
For bladder cancer, the pió0*4 gene was found to be frequently mutated and/or deleted in 
cell lines but not in primary tumors. In the Egyptian population, Bilharziasis associated 
bladder cancer is one of the most frequently occurring malignancies. The disease is 
characterized by a different etiology and histology than Transitional Cell Carcinoma. 
Therefore, we studied pi б1™4 mutations and deletions in these type of tumors and 
compared this to human bladder cancer cell lines and non-Bilharziasis associated 
Transitional Cell Carcinomas. PCR-SSCP analysis. Southern blot analysis or multiplex 
PCR were applied to 17 established bladder cell lines, 46 primary non-Bilharziasis 
associated bladder tumors and 47 Bilharziasis associated bladder cancers to examine 
pl6INK4 gene alterations. As described in chapter V, in cell lines we found 9 homozygous 
deletions and 1 mutation (59%) whereas in primary non-Bilharziasis associated bladder 
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tumors deletions were found in 4 of 22 samples analyzed (18%) and no mutations were 
detected in the 46 tumor samples screened. The higher frequency of alterations in cell 
lines probably reflects the fact that pl6INK4 alterations provide a strong selective advantage 
to cell proliferation once cells are established in culture. Interestingly, in Bilharziasis 
associated bladder cancer, deletions were present in 23 samples and mutations in a further 
2 cases (53%). These findings suggest that the pió"4144 gene alterations contribute 
significantly to the pathogenesis of Bilharziasis associated bladder tumors. No correlation 
was found between pl6INK4 alteration and histo-pathological data, i.e., the same 
frequency of alteration was found in tumors with different differentiation patterns 
(squamous, TCC or adenocarcinoma). 
In chapter VI we report on the putative role of l lql3 amplification in bladder 
carcinogenesis; more precisely, we studied the amplification of this chromosomal region 
and the expression of 4 candidate oncogenes mapped to this region: cyclin Dl, FGF3, 
FGF4 and EMS1. Whereas both cyclin Dl and EMS1 are expressed at higher level in 
tumors with amplifications, no expression of FGF3 and FGF4 could be detected. 
Interestingly, the increased expression of cyclin Dl and EMS1 seems to occur in 
superficial and not in invasive tumors. Moreover, in 9 tumors that have a low expression 
of cyclin Dl and EMS1, a highly malignant phenotype was observed. These findings 
suggest that the more aggressive tumors develop through a cyclin D1/EMS1 independent 
pathway. 
Although the parameters studied in this thesis did not prove to be of direct clinical 
interest, we have exemplified here that tumors can develop through different molecular 
pathways. The progressive unravelling of these pathways should lead to sub-classification 
of tumors with hopefully clinical applicable diagnostic procedures. 
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SAMENVATTING 
Zoals beschreven staat in Hoofdstuk I is prostaatkanker een van de meest voorkomende 
urologische tumoren. Bovendien is prostaatkanker de op een na meest voorkomende 
doodsoorzaak door kanker bij mannen in de westerse populatie. Ondanks alle 
inspanningen is er nog maar weinig bekend over de genetische veranderingen die leiden 
tot het ontstaan en de progressie van prostaat- en blaaskanker. Met de ontwikkeling van 
moleculair biologische technieken zijn er methoden beschikbaar gekomen om meer inzicht 
te krijgen in het complexe proces van tumorigenese. Deze experimenten leiden niet alleen 
tot een beter begrip van de transitie van een normale cel naar een kwaadaardige tumorcel 
maar ook komen er nieuwe diagnostische methoden en/of nieuwe targets voor therapie 
beschikbaar. 
Hoofdstuk II beschrijft het gebruik van RNA in situ hybridisatie (RISH) om de 
waarde van HMG-I(Y) als progressiemarker te onderzoeken. HMG-I(Y) is een high 
mobility group protein waarvan eerder al overexpressie in ongedifferentieerde en 
prolifererende cellen gerapporteerd was. Een groep van 71 patiënten met prostaatkanker is 
geanalyseerd m.b.v. RISH en de resultaten zijn gekwantificeerd m.b.v. beeldanalyse. In 
zowel benigne hyperplasie van de prostaat (BPH) en normale prostaat werd geen 
detecteerbare expressie van HMG-I(Y) gevonden. Alleen in prostaattumorweefsel werd 
een hoog expressie niveau gevonden. Er kon een statistisch significante correlatie tussen 
het expressieniveau van HMG-I(Y) en (Gleason) graad / klinische stagiëring (TNM) 
aangetoond worden. Omdat er maar weinig 'follow-up' data beschikbaar waren kon er 
geen conclusie getrokken worden over de waarde van HMG-I(Y) als prognostische 
marker. Uit de vergelijking van de resultaten verkregen m.b.v. vriescoupes met die van 
paraffmecoupes bleek dat archiefmateriaal bruikbaar was voor deze RISH methode. 
Daarom werd er een grote retrospectieve studie gedaan om te kijken of er een correlatie 
bestaat tussen HMG-I(Y) expressie niveau en overleving en dat is het onderwerp van 
Hoofdstuk m. 
Een groep van 102 radicale prostatectomiën werd geanalyseerd voor HMG-I(Y) expressie 
m.b.v. RISH. De resultaten zijn gekwantificeerd m.b.v beeldanalyse. Een 'follow-up' van 
19-62 maanden (gemiddeld 53 maanden) was beschikbaar. Een correlatie tussen 
HMG-I(Y) expressie en zowel (Gleason) graad en (TMN) stagiëring werd bevestigd. Dit 
was in overeenstemming met de resultaten die in hoofdstuk II beschreven staan. 
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Bovendien kon er een significante correlatie tussen HMG-I(Y) expressie en progressie 
aangetoond worden (chi-square=5,0175, P=0,025). Een direkte relatie tussen HMG-I(Y) 
expressie en biochemische progressie (i.e. stijging PSA>0.5 ng/ml) werd aangetoond 
in deze studie. Echter, een multivariate analyse waarin (Gleason) graad, tumorstagièring, 
HMG-I(Y) expressie en PSA niveaus werden vergeleken wees (Gleason) graad aan als de 
meest betrouwbare prognostische parameter. Ondanks het feit dat HMG-I(Y) expressie 
niveaus een indicatie geven voor een slechte prognose kon er geen additionele waarde 
aangetoond worden boven de subjectieve graderings methoden. 
Recent zijn er verschillende cel-cyclus regulatoren, zoals cyclines, cycline afhankelijke 
kinases en cycline afhankelijke kinase Inhibitoren geïdentificeerd en er zijn aanwijzingen 
dat deze moleculen een belangrijke rol spelen bij het ontstaan van kanker. In het tweede 
gedeelte van dit proefschrift worden er studies beschreven die er op gericht zijn de 
vermeende rol die cycline afhankelijke kinase inhibitor pl6INK4 en cycline Dl in prostaat-
en blaascarcinogenese spelen op te helderen. 
Het gen voor cycline afhankelijk kinase-4, pl6INK4, is gelokaliseerd op chromosoom 9p21, 
een 'hot spot' voor chromosomaal verlies in verscheidene humane tumoren. Homozygote 
deleties van dit gen worden met hoge frequentie gevonden in cellijnen van verschillende 
typen tumoren hetgeen wijst op een rol als tumorsuppressorgen. In Hoofdstuk IV hebben 
we PCR-SSCP analyse gebruikt om de frequentie van pl6INK4 mutaties en/of deleties van 
exon 1 en exon 2 in prostaatkanker te bepalen. Twintig primaire tumoren en vier cellijnen 
werden onderzocht op mutaties en/of deleties van het pl6INK4 gen. In tegenstelling tot de 
meeste voorafgaande studies werden er geen homozygote deleties gevonden in prostaatcel-
lijnen. Er werden echter wel drie SSCP-shifts gevonden in exon 2. In de humane 
prostaatcellijn DU145 werd een mutatie in codon 76 aangetoond. In primaire tumoren 
werden twee mutaties m.b.v sequentieanalyse bevestigd: een mutatie in codon 55 (leucine 
naar proline) en een in codon 140 welke waarschijnlijk correspondeert met een 
polymorfisme. Deze data suggereren dat mutaties en/of deleties van het ріб"1*4 gen niet 
vaak voorkomen in prostaatkanker. 
Het pló"™4 gen is vaak gemuteerd en/of gedeleteerd in blaaskankercellijnen maar niet in 
primaire tumoren. In de Egyptische bevolking is Bilharzia geassocieerde blaaskanker de 
meest voorkomende vorm van kanker. De ziekte heeft een andere etiologie en histologie 
dan de overgangscel-carcinoma's zoals deze zich veelal in de westerse bevolking presente-
ren. Daarom is er gekeken naar eventuele ріб"4*4 mutaties en/of deleties in dit type 
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tumoren en hebben we deze vergeleken met blaaskankercellijnen en niet-Bilharzia 
geassocieerde overgangscel-carcinomas. PCR-SSCP analyse, Southern blot analyse of 
multiplex PCR zijn gebruikt om 17 blaaskanker cellijnen, 46 primaire niet-Bilharzia 
geassocieerde blaastumoren en 47 Bilharzia geassocieerde blaastumoren te onderzoeken op 
veranderingen in het ріб11^4 gen. Zoals beschreven in Hoofdstuk V werden in de 
cellijnen 9 homozygote deleties en 1 mutatie gevonden (59%) terwijl er in primaire 
niet-Bilharzia geassocieerde blaastumoren deleties gevonden werden in 4 van de 22 
monsters (18%). In geen enkele van de 46 geanalyseerde monsters werd een mutatie 
gevonden. De hogere frequentie in cellijnen weerspiegelt waarschijnlijk het feit dat 
pjgiNK4 veranderingen een sterk selectief voordeel geven voor celproliferatie zodra deze in 
weefselkweek gebracht worden. Een interessant gegeven is dat in Bilharzia geassocieerde 
blaastumoren in 23 monsters deleties en in 2 monsters mutaties gevonden werden (53%). 
Deze bevindingen suggereren dat veranderingen in het ріб""*4 gen significant bijdragen in 
de Pathogenese van Bilharzia geassocieerde blaastumoren. Er werd geen correlatie 
gevonden tussen ріб 1 ^ 4 veranderingen en histo-pathologische data, dezelfde frequentie 
van veranderingen werd gevonden in tumoren met verschillende differentiatie patronen 
(squamous, ТСС of adenocarcinoma's). 
In hoofdstuk VI wordt gerapporteerd over de vermeende rol van l lql3 amplificatie in 
blaaskanker ontwikkeling; om precies te zijn, de amplificatie van deze chromosomale 
regio en de expressie vah vier kandidaat oncogenen die gelokaliseerd zijn in deze regio: 
cycline Dl, FGF3, FGF4 en EMS1. Terwijl zowel cycline Dl als EMS1 hoog tot 
expressie komen in tumoren met amplificaties werd er geen expressie van FGF3 en 
FGF4 waargenomen. De verhoogde expressie van cycline Dl en EMS1 bleek 
voornamelijk voor te komen in oppervlakkige maar niet in invasieve tumoren. 
Daarenboven bleek dat 9 tumoren met een lage expressie van cycline Dl en EMS1 juist 
een zeer aggressief phenotype hadden (histologie, stagiëring). Deze bevindingen 
suggereren dat de meer aggresieve tumoren zich ontwikkelen via een cycline D1/EMS1 
onafhankelijke weg. 
Alhoewel van de parameters die bestudeerd zijn in dit proefschrift niet bewezen is dat ze 
van direct klinisch belang zijn, is hier wederom aangetoond dat tumoren zich kunnen 
ontwikkelen via verschillende moleculaire wegen. De opheldering hiervan moet leiden tot 
subklassificatie van tumoren, hetgeen kan leiden tot meer adequate diagnostische 
procedures. 
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